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Abstract 
Multiple sclerosis (MS) is a chronic and immune-mediated central nervous system condition 
characterized by inflammation and demyelination. Large genome-wide association studies 
(GWAS) have identified 110 non-human leukocyte antigen (HLA) and several HLA MS risk 
variants. However, the relationship between MS risk-associated single nucleotide 
polymorphisms (SNPs) and MS clinical course has not been well studied. Despite good 
success in identifying a number of risk variants, several large GWAS studies have made 
comparatively little progress in finding associations with MS clinical course. Moreover, these 
risk SNPs only can explain 28% of MS risk. This brings one question: whether these risk 
SNPs influence MS clinical course?  
This thesis first presents an overview of MS, including its clinical symptom & diagnosis, the 
epidemiology of MS, and particularly the role of genetic factors in MS. Following from this is 
the report of my work evaluating the role of MS risk-associated single nucleotide 
polymorphisms (SNPs) in modulating clinical course in early MS. Utilising a longitudinal 
cohort study of persons who have had a first demyelinating event suggestive of, but not yet 
diagnostic of MS and then followed for five years, we found:  
 Seven non-HLA SNPs predicted relapse and/or CDMS, and seven other non-HLA
SNPs predicted the annualised change in disability status (ΔEDSS, as measured by
Expanded Disability Status Scale).
 Following from this, we generated two genetic risk scores (GRS) based on those
identified risk SNPs associated with CDMS/relapse and disability progression, which
each significantly predicted each outcome in a significant, dose-dependent manner:
o Patients having >5 risk genotypes had a 6-fold greater risk of CDMS and
relapse compared to those with <2;
o Those carrying ≥6 risk genotypes progressed at 0.48 EDSS points per year
faster compared to those with <2, and the CGRS model explained 32% of the
variance in disability.
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In summary, our findings of longitudinal data demonstrate that MS susceptibility genes 
predicted worse MS clinical course (that is, conversion to active disease, relapse risk and 
disability progression), suggesting that the genetic drivers of MS progression are polygenic. 
These findings may aid in targeting patients of high disease risk and potentially in early 
prevention and treatment, but replication is warranted. 
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Chapter 1. Introduction  
1.1 Multiple Sclerosis  
 
Multiple sclerosis (MS) is a chronic and immune-mediated central nervous system (CNS) 
condition characterized by inflammation and demyelination (1) with typical onset between 20 
and 40 years old (2). While most patients present with the relapsing-remitting type, virtually 
all patients have some degree of disability progression over time, some catastrophically so. It 
is estimated that 2.3 million people are affected by MS globally, with a high prevalence 
(1/1,000) in Caucasian populations and with a high female/male sex ratio (1.5 to 2.5).  
1.2 Clinical symptom and course of MS 
 
Patients with MS can present with a range of symptoms, including limb weakness & muscle 
spasms, paraesthesia, vision problem (eye pain/dysfunction), balance issues, headache and 
ataxia, as well as bladder, bowel and sexual dysfunction; a majority of patients may also 
experience cognitive decline. Patients with MS may only have one or several of these 
symptoms at any one time and over the course of their disease.  
1.2.1 MS Clinical course 
MS clinical course comprises both onset (risk) and progression (relapse & disability 
progression). The components and stages of the disease in MS can be charactered as clinically 
isolated syndrome (CIS), first demyelinating event (FDE), clinically definite multiple 
sclerosis (CDMS), relapse and disability progression. The initial presentation in MS typically 
takes the form of a clinically isolated syndrome, usually a first attack of symptoms compatible 
with MS, such as optic neuritis, which while clinically significant is insufficient to merit a 
diagnosis of MS. Diagnosis of MS requires further evidence in support of actual disease, 
often in the form of a second episode substantiating dissemination of demyelination in time 
(serial and distinct episodes) and space (affecting different parts of the brain). This evidence 
Chapter1: Introduction 
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can also come from magnetic resonance imaging (MRI) lesions which can show 
dissemination in time and space, will have progression to CDMS (3-6).  
The two key aspects of MS, at least clinically, are relapse and progression. A relapse (also 
known as an attack or exacerbation) refers to clinical symptoms or signs typically manifested 
as an acute inflammatory demyelinating event in the CNS(6). Clinically, a minimum duration 
of 24 hours for a relapse is typically required while in most cases this is much longer. 
Progression is characterized as a sustained loss of neurologic function or increased disability. 
It is from these two primary clinical elements of MS, relapse and disability progression, that 
define its three main clinical phenotypes: relapsing-remitting (RRMS), secondary progressive 
(SPMS), and primary progressive MS (PPMS) (Figure 1)(7). RRMS is the most common 
course of the disease. It is characterized by unpredictable but clearly defined relapses of new 
symptoms or increasing severity of existing symptoms, followed by periods of partial or total 
recovery (remissions). Of those RRMS patients, about two in three will develop to SPMS, a 
disease phase in which relapses cease but a greater degree of sustained disability progression 
occurs. A minority of MS patients, usually thought to be around 10%, present in the primary-
progressive form, having no relapses during the course of their disease but instead suffering 
sustained disability progression from onset. The insidious nature of disability progression, 
particularly in patients who have no understanding of what is transpiring, makes the 
identification of the onset of this condition, and to a lesser extent its diagnosis, a more 
complicated affair in comparison to the relapsing-remitting type. In addition to these classic 
three types of MS is a somewhat less definite progressive-relapsing type (PRMS), which 
features the same insidious onset and progressive nature of PPMS, but with somewhat 
infrequent exacerbations of disability equated with relapses(8). 
Chapter1: Introduction 
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Figure 1 The potential clinical phenotype in different clinical phases in early MS. FDE: first 
demyelination episode. CDMS: clinically definite MS. CIS: clinically isolated syndrome. 
EDSS: Expanded Disability Status Scale. MSSS: Multiple Sclerosis Severity Score. RRMS: 
relapsing remitting MS. PPMS: primary progressive MS. SPMS: secondary progressive MS. 
CCA: Corpus callosum atrophy. 
1.2.2 Measurement of disability progression 
The most widely used method of quantifying disability in MS is the Expanded Disability 
Status Scale (EDSS) developed by a neurologist called John Kurtzke, based on the 
dysfunction of eight functional systems(9). The total EDSS scale ranges from 0 to 10 (normal 
to death), in a 0.5 unit increment (except the first interval which just goes from 0 to 1.0). 
Another measure of progression is the multiple sclerosis severity score (MSSS)(10) which 
adjusts the absolute level of disability by EDSS for the duration elapsed since symptom onset, 
such that persons with equivalent disability but the shorter duration will have a greater MSSS 
than someone with a longer duration. While relapses are acutely impactful on patient’s quality 
of life, the sustained and irreversible nature of disability progression makes it highly 
correlated with quality of life. 
Chapter1: Introduction 
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1.3 Diagnosis and treatment of multiple sclerosis 
The mean age of MS onset is presently thought to be around 30 years, and most people are 
diagnosed between 25-30 years old. Around 3-5% of diagnosed MS patients are under 18 
years old (11, 12); a separate condition, paediatric-onset MS, presents before the age of 10. 
The main requirement for MS diagnosing is the demonstration of central nervous system 
disorder, based on a combination of clinical and MRI findings. Both physical and Magnetic 
resonance imaging (MRI) test are important for MS diagnosis. MRI always provide evidence 
to support the MS clinical diagnosis. The gold MS diagnostic criteria for MS, McDonald 
Criteria, also include specific criteria for MS MRI testing. 
1.3.1 Gold standard for diagnosis of MS 
Since it was first developed in 2001 by the International Panel on the Diagnosis of Multiple 
Sclerosis(4), the McDonald criteria has become the most popular one for MS diagnosis. This 
criteria requires clinical and laboratory assessments to indicate dissemination of CNS 
demyelinating lesions in space and in time, that is affecting different parts of the brain/spinal 
cord and being distinct episodes rather than one confluent episode. As newer evidence 
accumulates, this criteria has since been revised two times in 2005(5) and 2010(6), primarily 
to simplify the MRI diagnostic criteria while maintaining diagnostic sensitivity and specificity 
(Figure 1.2). 
Chapter1: Introduction 
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Figure 1.2: McDonald criteria 2010 revisions (adapted from Polman et al.(6)) 
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1.3.2 Magnetic resonance imaging support the diagnosis of MS 
Magnetic resonance imaging (MRI), is a medical imaging test that is used to image the 
physiological processes of the brain. MRI has become the preferred imaging method to help 
diagnose MS and to monitor its clinical course, as highlighted by above-mentioned the 
McDonald diagnostic criteria for MS, which incorporate detailed standards for dissemination 
in space and time as demonstrated by MRI (Figure 1.2). 
Cerebral or spinal plaques are the characteristic lesions for MS patients, showing as bright 
images on T2 weighted MRI. The plaque of MS focal lesions can be neat-edged and round, 
oval or irregular in appearance and arranged at right angles to the cerebral hemisphere and 
corpus callosum on MRI. When viewed on MRI sagittal images, a typical element is the 
Dawson finger (Figure 1.3). Dawson finger is a demyelinating plaque through the corpus 
callosum. Patients can have one or most of these characteristics. The size of a plaque varies, 
usually from a few millimeters to 1cm. Plaques can be found in the temporal lobe, internal 
capsule, cortex, and cerebellum region. Over the disease course, the cumulative impacts of 
neuroinflammation can manifest as a degeneration and atrophy, particularly evident in 
patients with severe MS. The frequency of spinal cord lesions are less common in European- 
descent populations, but more common in Asian populations (13). They are more commonly 
found in the cervical and thoracic spine on MRI, and usually located in the outer periphery of 
the spinal cord white matter, mostly seen as a small plaque. The size of these plaques is at 
least at 3mm but not more than two vertebral segments in length(14).(Figure 1.4) 
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Figure 1.3: The Dawson Fingers (From Radiology MRI 
http://radiologymri.blogspot.com.au/2012/01/proton-density-in-multiple-sclerosis.html) 
  
Figure 1.4: T2-weighted sagittal view of spinal cord, which shows a hyperintense lesion in 
cervical spinal cord(15).  
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1.3.3 Treatment of MS 
As the cause of MS remains unclear, as yet there is no cure. Treatments only can relieve 
symptoms and delay the progression of MS (16). Methylprednisolone can be taken as 
infusions or pills and is used to reduce neuroinflammation. It is useful in controlling the 
severity of MS attacks. Interferon-beta is one kind of useful treatment for MS. Interferon-beta 
is derived from the human cytokine that modulates immune responsiveness(17). Interferon-
beta medications are injected, either intramuscular or subcutaneous and act to reduce the 
severity and frequency of relapses in relapsing-remitting MS patients. Other medications such 
as glatiramer acetate which can prevent immune system’s attack on myelin are also widely 
used. Monoclonal antibodies (MAB) are one of the newest treatment for MS. This treatment 
is widely used to modulate the immune system by working on targets involved in MS 
development. This treatment seems to be more useful in both now and future. However, there 
is strong interest in developing drugs for progressive MS with several studies now showing 
some effect on preventing disability accumulation in primary progressive MS (Ocrelizumab) 
and in secondary progressive MS (glutathione and simvastatin), although reversal of disability 
has not been shown. 
 
1.4 The epidemiology of MS 
 
In the past several decades of research, epidemiology has made essential contributions to our 
understanding of MS, including its geographic distribution, its distribution in society, as well 
as identifying a number of significant risk or protective environmental factors, behaviors and 
genetic susceptibility variants.(18-21). 
1.4.1 The geo-epidemiology of MS 
 
Previous studies have shown a latitudinal gradient of MS prevalence, with a high prevalence 
of MS observed in areas of high latitude. Geographically, MS divided into several major 
Chapter1: Introduction 
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frequency areas(22), particularly in the most part of Europe, Canada, the northern United 
States and southeastern Australia (ranging from 58-116/100,000); in many parts of these 
areas, the prevalence is more than 100/100,000; the Orkney Islands have the highest global 
prevalence of 300/100,000(23). The southern United States, South Africa, northern Australia, 
most parts of Russia and some parts of Latin America have a prevalence ranging from 10 to 
60/100,000, representing medium frequency areas. Southeast Asia and Africa have the lowest 
prevalence, generally between 0 and 10. These data, derived from countless local and regional 
epidemiology studies, are summarised in the “Atlas of MS”, an online and text-based resource 
produced by the MS International Federation. The 2013 Atlas of MS reported a total number 
of persons with MS globally of nearly 2.3 million, and showed a significant sex ratio in MS 
prevalence, with the female prevalence more than three times that of males. Western and 
European-descent countries have the highest prevalence estimates of MS, according to the 
latest data shown in Figure 1.5. Although MS is found worldwide, it is less common in Asian 
populations and quite rare in Aboriginal populations such as the Inuit, Māori, Eskimo and 
Australian Aborigines. The mean age of MS onset is nearly 30 years, though studies indicate 
the mean age of onset is a few years earlier in females than males. According to the latest 
Survey of Disability, Ageing & Carers (SDAC) in 2009, there were 23,700 Australians 
affected by MS. The national prevalence was 95.2/100.000, though the frequency is much 
greater at higher latitudes like Tasmania than northern latitudes like Queensland (24). 
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Figure 1.5: The worldwide prevalence of MS (adapted from Atlas of MS 2013). 
1.5 The environmental factors associated with MS 
 
With the development of MS pathogenic mechanisms research, considerable evidence 
indicates that environmental factors play an important role in the aetiology of MS. Although 
all the environmental factors affecting MS development have not yet been established, 
accumulating evidence has strongly implicated several environmental factors, including 
Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) infection, vitamin D deficiency 
and low ultraviolet (UV) exposure, and tobacco smoking. 
1.5.1 Virus infection (EBV & HHV-6) 
 
EBV, is one of the most common human viruses, it is a double-stranded DNA γ-herpesvirus. 
This virus manifests as a latent infection within B-cells after they are infected (25). It has 
been demonstrated that EBV infection is associated with MS risk, with almost a hundred 
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percent detection rate in MS patients (26). Higher rates of EBV seropositivity have been 
identified in MS patients comparing with controls(27). However, infectious mononucleosis 
history is also a risk factor for MS, which supports the EBV association. In a study of US 
military personnel, the risk of MS among those who had anti-EBNA titres > 320 units was 36-
times higher than those who had titres < 20 (28). Of note, infection with EBV during 
adolescence showed a further 2-3 fold increased the risk of developing MS(29). However, one 
study found that the reactivation parameters of EBV were not associated with MS clinical 
course, and this is supported by a subsequent independent 5-yr prospective study, which did 
not show any associations between EBV levels and MS activity and progression(30). These 
findings may suggest that while some MS environmental risk factors are also associated with 
MS progression, others may only influence the onset. 
 
Human herpesvirus-6 (HHV-6; two types, i.e., HHV-6A and HHV-6B), first discovered by 
Salahuddin and colleagues in 1986(31). There is increasing evidence demonstrating that this 
virus has a potential role in the pathogenesis of MS. It is found that one in four of MS 
patients’ saliva and plasma had HHV-6B DNA (32). Although this virus can also be found in 
plasma from healthy people, low MS disease activity patients had a  lower frequency of 
HHV-6B positive samples than those having high disease activity (32). Moreover, the 
reactivation of HHV-6A has been associated with two genes (IRF5 and MHC2TA rs4774C), 
which have been previously related to increased MS susceptibility (33). Importantly, serum 
DNA levels of HHV-6 have been reduced after treatment with interferon beta, while patients 
had poor outcomes (e.g., more relapses and a lesser reduction in relapse rate) when their 
HHV-6 DNA levels were not reduced by therapy (34). Nevertheless, more longitudinal 
studies are needed to confirm the association between HHV-6 and MS risk and clinical 
course, and RCTs are needed to explore useful treatment for MS targeted at clearing this 
virus. 
1.5.2 Vitamin D & UV exposure 
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Vitamin D deficiency has been considered as a risk factor for many complex diseases such as 
MS. Recent studies have shown that low vitamin D levels play an important role on MS risk. 
A large number of epidemiological data indicated that there is a high prevalence of MS in 
high-latitude and low ultraviolet radiation (UVR) areas, in contrast to the low prevalence of 
MS in low-latitude and high UVR areas. This may be because vitamin D3 is produced 
photochemically from precursors in the skin by UVR exposure(35). In the liver, vitamin D3 
converted to the circulating form, 25-hydroxyvitamin D, and then converted to 1,25-
dihydroxyvitamin D in kidney cells, as well as in other cell types, particularly neuroglial and 
immune system cells. Vitamin D play an essential role in modulating the immune response.  
 
Now, it is well established that Vitamin D in humans mainly comes from sun exposure. 
Vitamin D play an essential role in the synthesis of myelin. Vitamin D as an environmental 
factor, may not only influence whether a person will get MS but also may impact the clinical 
course of MS. The involvement of vitamin D in MS onset and progression was related to the 
essential role that vitamin D pathway plays in the autoimmune system. The immune system 
are regulated by combining of the active form vitamin D (hydroxylates 25-hydroxyvitamin D) 
with the specific vitamin D receptor (VDR); and the function of VDR is regulated by its 
genetic structure. There are many restriction sites such as Bsm I and Apa I in the VDR gene. 
One study suggests that the polymorphisms of the VDR gene may be associated with MS 
risk(36). However, this finding was not confirmed by a meta-analysis(37).  
 
Simpson and colleagues found that each 10nmol/l increase in vitamin D resulted in a nearly 
12% reduction of MS relapse risk by using survival analysis(38). This is the first longitudinal 
cohort study to investigate the relationship between vitamin D and relapse of RRMS patients. 
The recent subsequent study shows evidence that Vitamin D plays an important role in myelin 
repair. This study finds vitamin D activated RXR gamma receptor protein and this protein 
was important in MS patients’ myelin repairing (39). This finding functionally explained the 
relationship between the vitamin D level and progression of MS and indicated that vitamin D 
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could be a target for the future myelin repair drug and a possible treatment for people with 
MS. In short, compared to other MS treatment, vitamin D based treatment are cheaper with 
fewer side effects. It is easier for people to increase vitamin D level by sun exposure and daily 
intake. 
 
1.5.3 Tobacco smoking 
 
Tobacco smoking has been considered as a risk factor of MS for many years. In addition, 
recent studies have demonstrated that tobacco smoking influence both risk of developing MS 
and MS progression (relapse and disability)(40, 41). Studies have indicated that those tobacco 
smokers have a greater risk of MS compared to those non-smokers; and MS risk is also 
associated with the duration and intensity of smoking (42, 43). One recent study has shown 
patients who smoked at least 10 cigarettes per day had a higher risk than never-smokers of 
progressing to secondary progressive MS(40). While the mechanism by which smoking is 
related to MS onset and progression remains uncertain, it has been suggested that this may be 
partly explained by inflammation or immune dysfunction (44). 
1.6 Genetic research in MS 
 
Although the aetiology of MS is not yet fully understood, genetic factors have been shown to 
play a crucial role in MS risk. However, little is known about the role of genetic factors in MS 
clinical course, including clinically definite MS (CDMS), relapse and disability progression 
(2, 45). In the last two decades, a total of 110 non-HLA region genetic loci and several HLA 
genetic loci associated with MS susceptibility have been identified by genome-wide 
association studies (GWAS)(46). However, only 28% of the perceived heritability of MS can 
be explained by those genetic loci and large GWAS have not found any associations between 
these MS susceptibility genes and MS clinical course. Therefore, what explains the missing 
heritability and whether genetic factors have potential roles in modulating MS clinical course 
needs to be answered. 
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In addition to the previously mentioned potential role of differential UVR exposure in 
mediating the latitudinal variation in MS, some studies have suggested a role for genetic 
factors due to differential migration and genetic risk. The incidence of MS in Western 
countries is higher than that in Asian countries. Kira found that MS incidence rate is very low 
in low-latitude regions, such as South America and Africa, which is related to the low 
frequency of HLA-DR2 gene(47). Some ethnic groups, such as Eskimos, Aboriginal 
populations in North America, Australia & New Zealand, and Romani, have lower 
frequencies of MS, suggesting a role for genetic factors in MS susceptibility.  
 
The hypothesis that genetic factors may be the main determinants of MS familial aggregation 
was first implied by the observation of clustering of MS in families based on the results of the 
previous family and twin studies. In line with previous work(48), the Canada twin study 
demonstrated the concordance rate in monozygotic twin (25.3%) was four times more than 
that seen in dizygotic twin(5.4%)(49). It has also been suggested that the children’s 
recurrence risk is influenced by both parents’ genetic background (50). These data, long 
recognised and continuing to the present, provided the initial evidence in support of a genetic 
component to MS, and that this effect is polygenic. However, even while there is a recognised 
genetic element to MS, the fact that the concordance rate in monozygotic twin is only 30% 
suggests that environmental exposures also influence individual’s risk to MS.  
1.6.1 Linkage and Candidate analysis in MS genetic research 
 
The main findings of this period are the HLA II area associated with MS onset which was 
confirmed by linkage and candidate gene approaches. Based on these findings, linkage and 
candidate gene approach were used to estimate the effect of substantial MS risk genes. 
Linkage analysis is a powerful tool based on the findings that genes located physically close 
together on a chromosome during the meiosis phase are inherited together as a block.(51) 
Linkage analysis became the primary mode of statistical genetic mapping of Mendelian and 
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complex diseases with familial aggregation in early genetic research. Linkage study based on 
family data has been useful to examine the effect of specific genes associated with Mendelian 
(i.e., monogenic) diseases, but it has been less effective in identifying susceptibility genes of 
polygenic complex disease such as MS. In 2007, the International Multiple Sclerosis Genetics 
Consortium (IMSGC) established the largest non-parametric genome-wide linkage screen in 
931 MS family trios. The important result for this study was identifying the significant 
linkage within the HLA locus, with a peak in the regional logarithm of the odds (LOD) score 
of 11.7, while none of the loci outside the HLA locus reached statistical significance. Then, 
lots of studies investigated genetic factors involved in MS onset, however no validated new 
susceptibility genes were identified. The HLA-DRB1*15:01 allele had the greatest effect on 
risk of that region area. Generally, given the complexity of MS, and the potential for gene-
environment interaction, linkage and candidate gene studies have not been successful at 
finding susceptibility loci outside the MHC region in MS. Partly this is because these studies 
are limited by small sample size, as well as the small number of candidate variants available 
for previous analyses.  
 
1.6.2 Genome-wide association studies and success for MS genetic research 
 
Researchers found that common variants in many genes outside the HLA region will each 
have small effects on the risk of complex diseases such as MS (OR up to 1.30 for non-HLA 
SNPs (52)). According to these findings, the focus of genetic studies has shifted from linkage 
analysis to association analysis of the common variants in complex disease because 
association analysis studies are more successful than linkage methods in searching disease 
risk variants. Thus, automated chip based GWAS testing using millions of genetic variation 
marker, the single nucleotide polymorphism (SNP) was developed , and has become the 
favoured genetic mapping method to investigate the genetic structure of complex disease (53). 
Many GWAS have often used a multistage design. In Stages One and Two, well-established 
case and control samples are genotyped by GWAS chips. A representative Cartesian plot 
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needs to be presented to show the DNA were successfully genotyped. In the quality control 
and data cleaning stage, microarray quality, genotype completion rates, Hardy-Weinberg 
equilibrium analysis, sex inconsistency tests, parent offspring genotype incompatibilities, 
principal components analysis and removing bad variants and poor performing subjects need 
to be undertaken. Finally, statistical analysis is performed by testing individual SNPs for 
association by using appropriate regression models for quantitative traits. The statistical 
significance (P-value) must be adjusted for the number of tests to reduce the risk of false 
positives. A threshold of 5.0x10-8 is typically defined as genome-wide significant.  
 
Although GWAS have discovered many SNPs predicting a number of conditions (54), some 
major challenges have been raised.  
1) Ethnicity mix, referred to as population stratification, is a particular kind of 
confounding. People from different ancestries have a different allele frequency in 
some SNPs (55). GWAS can be confounded by population stratification which can 
lead to an increasing number of false positive results. The way to correct population 
stratification bias is to measure this confounder and adjust for it in regression models, 
or to stratify the cases and controls removing outliers at the time of principal 
components analysis.   
 
2) Multiple comparisons adjustment. Statistical significance is usually defined as 
p<0.05 in classic epidemiological studies. However, for GWAS, the significance 
threshold must be adjusted to account for the substantial number of tests for SNPs. 
Bonferroni correction is widely used for multiple comparison adjustment. The 
Bonferroni method sets GWAS statistical significance at p=0.05/N. However, this 
method is sometimes considered to be too strict a criterion because some tests are not 
independent. In GWAS, many SNPs are in linkage disequilibrium (LD), which means 
they are correlated. To deal with this, the high number of test needs to be replaced. 
There are two common approaches to deal with this problem: 1) to calculate the true 
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number of independent tests(56);  2)  to use the false discovery rate (FDR) method to 
adjust the FDR for an independent test, which has been shown to be effective at 
improving statistical power (57). These methods suggest a genome significant 
threshold between 10-6 and 10-8, but the classic GWAS threshold of 10-8 remains 
widely used. 
 
The first MS GWAS paper was published in 2007 by IMSGC(58) (Table 1). This paper, 
testing 334,923 SNPs in 931 cases, identified polymorphisms in HLA-DRA locus (p=8.94x10-
81), IL2RA (P=2.96x10-8) and IL7RA (p=2.94x10-7) as risk factors for MS. The IL7RA gene 
finding was subsequently replicated in other MS studies(59, 60).This paper opened a new era 
in MS genetic research. Since this publication, 16 genome-wide association studies have been 
published (Table 1).The first large MS GWAS study in Australia and New Zealand(61) was 
published by the ANZGene Collaboration, which established a genome-wide association 
study of 1,618 cases and 3,413 controls. They identified six new susceptibility variants on 
chromosomes 12 and 20. This study also confirmed several previously identified MS risk 
variants. 
Table 2: List of major GWAS in MS genetic research 
 
 Year Population 
Number 
of cases 
Number of 
controls 
IMSGC 2007 USA,UK 931 1,862 
WTCCC1 2007 UK 975 1,466 
Comabella  2008 Spain 242 242 
Aulchenko 2008 Netherlands 45 195 
Baranzini 2009 Various 978 883 
De Jager 2009 USA 860 1,720 
ANZgene 2009 AU, New Zealand 1,618 3,413 
Sanna 2010 Sardinia 882 872 
Nischwitz 2010 Germany 590 825 
Chapter1: Introduction 
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Jakkula 2010 Finland 68 136 
IMSGC,WTCCC2 2011 Various 9,772 17,376 
Patsopoulos 2011 Various 1453 2176 
Matesanz 2012 Spain 296 801 
Martinelli 2012 Italy 197 234 
IMSGC 2013 European 14,498 24,091 
IMSGC 2015 European 17,465 30,385 
 
1.6.3 HLA loci associated with MS 
 
The HLA region of the genome encodes the major histocompatibility complex (MHC). MHC 
region is a key element of adaptive immunity and spans a region of about 4,000Kb located on 
the short arm of chromosome 6 at band position 6p21.3. It is the most complex genetic 
polymorphism system of the human genome. The MHC region is divided into three major 
regions: HLA class I, encoding the MHC I proteins; class II, encoding the MHC II proteins; 
and class III, which are partly of unknown function but appear to play some role in the 
general immune function and regulation(62). The HLA class I and class II region are the most 
polymorphic region in human DNA sequences, leading to a great variety of genotypes, this a 
valuable component of adaptive immune recognition of the diverse number of epitopes to be 
recognised. The class I region contains HLA-A, HLA-B and HLA-C genes, while the class II 
region contains HLA-DP, HLA-DQ and HLA-DR genes. Variants in this regions have been 
associated with most inflammatory and autoimmune disease such as multiple sclerosis.  
 
Bertrams and colleagues identified that HLA-A3 and HLA-B7 were associated with MS 
onset(63). Subsequent study has confirmed this finding(64). Altogether, HLA variants have 
explained 10.5% of the heritability of MS(65). Of the HLA loci, most studies have shown the 
HLA-DRB1*1501 locus to be the most strongly associated with MS risk (OR=3.1, 
Pcombined<10-320)(66-68), connoting a three-fold greater risk of MS(69). Several other HLA 
alleles and haplotypes have also been identified as risk factors of MS onset, but these appear 
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to vary in their association with risk by ancestry and ethnicity. Stankovich and colleagues 
investigated HLA associations in 1,230 MS cases in Australia, finding both HLA-DRB1*1501 
and HLA-DRB1*03 to be associated with MS risk (70). In Turkey and the Canary Islands, 
HLA-DRB1*04 was identified as a risk factors of MS(71), while in Sardinia, HLA-
DRB1*0301 and HLA-DRB1*0401 were identified as genetic risk factors(71). MS patients in 
Canada and Sweden were associated with HLA-DRB1*17(72). HLA-DRB1*1501 and HLA-
DQB1*0602 have an effect on in persons of African descent (67). Finally, even though Asian 
MS patients typically present as optico-spinal MS (OS-MS), in contrast to that seen in 
European-descent populations, MS patients in Japan also were associated with HLA-
DRB1*1501(73); and the incidence of MS patients with HLA-DRB1*0405 was significantly 
increased(74). Field and colleagues identified a relationship between MS and HLA 
DRB1*15:01, *0301, *0401, *1303, HLA-A*0201 and HLA-DPB1*0301 in 1,618 MS case 
and 3,413 controls of European descent (75). A SNP in an intron of HLA-DPB1, rs3135021, 
was also associated with MS in African Americans (68). In the same year, a Polish group 
identified that a polymorphism in the HLA-G gene was a risk factor for MS patients (76). In 
2012, Alcina and colleagues reported that the A allele of SNP rs3135388 in DRB1*1501 was 
associated with DQB1, DRB1 and DRB5 genes’ high expression in a Caucasian compared to 
G allele (77). These data demonstrate a significant role for the DRB1*1501 locus in MS onset. 
Not only are these loci associated with MS onset, but also there is some evidence showing 
that deleterious HLA genotypes like DRB1*1501 were positively associated with a marker of 
disease, oligoclonal bands (OB), while protective variants like DRB1*0405 were negatively 
associated with OB (78). These findings are useful in that they provide internal consistency 
and validation to HLA being associated with MS. Another study reported that the late onset 
MS was significantly associated with HLA-DRB1*0801 gene (79). In 2007, Silva reported 
DRB1*15 allele may be associated with a better MS clinical course (80). In 2009, Rama and 
other studies have found that HLA-DR15*1501 has a significant effect on the age of 
onset(AO) of MS among Caucasians and African-Americans (81). Figure 1.6 shows the HLA 
region’s genetic map and the risk of multiple sclerosis. 
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Figure 1.6 Genetic map of the HLA region and the risk of multiple sclerosis. (reproduced 
from Moutsianas and colleagues(82)) 
1.6.4 110 non-HLA common variants associated with MS 
 
During the last few decades, utilising candidate-gene, linkage studies, and GWAS 
approaches, at least 110 non-HLA genetic loci have been identified as associated with MS 
onset(52, 69, 83-86) (Appendix 1). In contrast, there has been comparatively less work into 
the genetic drivers of MS clinical course. The large GWAS have shown no significant loci 
that differentiate progressive-onset from bout-onset MS, even in cohorts enriched for 
progressive cases(61). Similarly, no association has been found with disability(84, 85, 87, 
88).This likely reflects the comparative difficulty in evaluating clinical course in genetic 
studies since MS clinical course (conversion to active disease, relapse, or disability 
progression) is not easily studied by GWAS, as GWAS are cross-sectional or case-control in 
design. While MS clinical course is best assessed longitudinally, and ideally in real time and 
from disease onset, so as to reduce potential impacts of reverse causality or heterogeneity by 
treatment or other disease aspects. Most of these 110 variants’ biological pathway still 
unclear, as yet, there are no benefits for MS treatment, based on GWAS result. In addition, 
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few relationships between these associated variants and MS progression were identified. One 
Western Australian study identified that HLA-DRB1*1501 was correlated with MS severity as 
measured by MSSS, and HLA-DRB1*1201 was correlated with less severe of MS (89). Our 
own studies also found some SNPs influenced MS clinical course (see Chapter 2). 
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Figure 1.7: The genomic map of 110 non HLA loci in Multiple Sclerosis (reported by 
IMSGC) 
1.7 The effect of genetic on MS clinical course  
1.7.1 Gene-environment interactions 
 
Studies have shown that environmental factors and genetic factors are the two principal risk 
factors for multiple sclerosis. The most well-known environmental risk factors for MS are 
vitamin D deficiency, smoking and EBV infection as discussed above(90). Studies have 
indicated that gene-environment interactions can explain a part of the MS genetic missing 
heritability. 
 
Lin and colleagues used Cox proportional hazards regression models to estimate the 
relationship between known MS common risk variants and MS relapse; and whether these 
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SNPs influence the 25-hydroxyvitamin D (25(OH)D) –relapse association among 141 RRMS 
patients in the Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study(45). They 
identified five variants associated with MS relapse with significant cumulative genotype risk 
effects, but also found three SNPs which modified the relationship between the hazard of 
relapse and serum 25(OH)D levels. Unfortunately, no risk variants were identified for MS 
disability progression. This study indicated that gene-environment interactions may play an 
important role in MS clinical course. It will provide support for the role of serum 25(OH)D in 
MS onset and progression. Similarly, another study using the same cohort showed protein 
kinase C (PKC) family genes-25(OH)D interactions modulate MS clinical course(91). In this 
study, they identified two SNPs tagging PRKCZ and PRKCH that interacted with 25(OH)D 
levels to influence relapse. However, the SNPs themselves were not independently associated 
with hazard of relapse. They also found two SNPs within the CYP2R1 and PRKCB that were 
associated with 25(OH)D levels and relapse. CYP2R1 has been previously identified to be 
associated with vitamin D levels in GWAS. The PRKCB gene has been previously associated 
with risk of rheumatoid arthritis and it is a member of the PKC gene family which is regulated 
by1,25 dihydroxyvitamin D (1,25(OH)D) in chondrocytes and mediated by VDR in 
downstream signalling pathways. These results suggest that gene-vitamin D interaction could 
be associated with MS clinical course. 
 
Similarly, the rate of progression of established MS is highly variable, e.g. monozygotic twins 
can have onsets of MS at significantly different ages, have completely different clinical 
presentations, and can progress at very different rates. This variability may be under genetic 
control or at least influenced by it. Currently, no genes have been found that influence 
different MS phenotype (PPMS vs. RRMS) or severity. The HLA-DRB1*1501 locus 
decreases the age of onset marginally (less than 2 years) (92). Therefore, it is likely that genes 
that interact with environmental factors (vitamin D, EBV) may significantly influence the rate 
of MS progression and determine the different MS phenotype. It is thought that secondary 
progressive MS and PPMS represent the same pathological process and that MS relapses may 
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represent a separate and additive inflammatory process more directly influenced by 
environmental determinants. 
Many research questions arise from the observation that a proportion of genetically 
susceptible individuals remain healthy while others develop MS. One potential answer is 
genetic heterogeneity, and the other is gene-environmental interactions. Genetic epidemiology 
implies that genetic background has an important complementary role in MS onset. As 
genetic factors remain the same in individuals, the environment determines the threshold of 
MS onset(93).  
1.7.2 Epigenetic contributions to MS 
 
It has been suggested that epigenetic mechanism may contributes to the pathophysiology of 
MS(94, 95). Epigenetics may alter MS risk gene’s expression. These changes may potentially 
mediate the response to environmental influences and result in functionally significant 
changes in gene expression. 
 
Epigenetics is defined as non- heritable changes in gene expression but not modifying the 
underlying DNA sequence(96). The epigenetic mechanisms consist of histone modification, 
DNA methylation and miRNA-associated post-transcriptional gene silencing(97). The major 
changes of epigenetic processes in cells are DNA methylation and histone deacetylation. That 
MS is usually transmitted to children more by female than male supports an epigenetic 
contribution(98).  
 
Epigenetic changes could explain much of the heterogeneity in MS clinical course. For 
example, gene methylation of MS patients’ peripheral blood mononuclear cells (PBMCs) 
found that DNA methylation may be used as markers of MS disease activity (99). A study on 
methylation changes in MS patients tested 56 candidate genes and found that 15 genes in the 
cell-free plasma DNA show methylation changes in MS patients compared to the healthy 
controls group, further, 5 of the 15 differentially methylated genes may also distinguish 
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patients with remission and exacerbation(99). One immunology study found that T(H)-17 
cell-associated MicroRNA-326 was correlated with MS severity. This means MicroRNA-326 
plays a critical role in T(H)-17 differentiation and could be associated with MS onset. A 
subsequent study found that MicroRNA-155 promotes the progression of autoimmune 
inflammation by enhancing T cell development (100). Another study showed that miRNA-
572 was significantly upregulated and downregulated during MS clinical course such as 
disease relapse and remission phases. This result indicated that miRNA-572 may be a 
biomarker for remyelination and modulates MS relapse and remission(101). These results 
suggest that microRNAs might be potential targets in the treatment of MS. However, 
significant further investigation of the role MicroRNA in MS treatment is needed. 
 
Though the epigenetics contribution to MS is just beginning to be understood, several 
mechanisms of epigenetic change in patients with MS have been identified. No doubt there 
will be more discoveries in the future. It has opened a new era in MS research. DNA 
demethylation of epigenetic, histone deacetylation and regulation mechanism of miRNA offer 
enticing prospect of new therapies for MS. There is a vast potential to use epigenetics for both 
MS preventive treatments and personalised therapies. It also brings a great hope to develop 
complex diseases’ molecular targeted genome research (102, 103). 
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Chapter 2. Known multiple sclerosis genetic susceptibility variants 
are associated with clinical course: a cohort study  
2.1 Abstract  
Background 
The genetic drivers of multiple sclerosis (MS) clinical course are essentially unknown with 
limited data arising from severity and clinical phenotype analyses in genome-wide association 
studies (GWAS).  
Methods 
Prospective cohort study of 127 first demyelinating events with genotype data, where 116 MS 
risk-associated single nucleotide polymorphisms (SNPs) were assessed as predictors of 
conversion to MS, relapse, and annualised disability progression (EDSS) up to 5-year review 
(ΔEDSS). Survival analysis was used to test for predictors of MS & relapse, and linear 
regression for disability progression. The top seven SNPs predicting MS/relapse and disability 
progression were evaluated as a cumulative genetic risk score (CGRS).  
Results 
We identified two non-HLA (rs12599600 & rs1021156) and one HLA (rs9266773) SNP 
predicting both CDMS and relapse risk. Additionally, three non-HLA SNPs predicted only 
conversion to MS; one HLA and two non-HLA SNPs predicted only relapse; and seven non-
HLA SNPs predicted ΔEDSS. The CGRS significantly predicted CDMS and relapse in a 
significant, dose-dependent manner: those having >5 risk genotypes had a 6-fold greater risk 
of CDMS and relapse compared to those with <2. The CGRS for ΔEDSS was also significant: 
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those carrying ≥6 risk genotypes progressed at 0.48 EDSS points per year faster compared to 
those with <2, and the CGRS model explained 32% of the variance in disability in this study 
cohort. 
Conclusions 
These data strongly suggest that MS genetic risk variants significantly influence MS clinical 
course and that this effect is polygenic.  
 
Keywords 
Multiple sclerosis, epidemiology, genetics, relapse, disability, EDSS, cohort, longitudinal 
study. 
2.2 Introduction 
 
During the last few decades, utilising candidate-gene, linkage studies and genome-wide 
association study (GWAS) approaches, at least 6 human leukocyte antigen (HLA) loci and 
110 non-HLA genetic loci have been identified as associated with multiple sclerosis (MS) 
onset (1-6). In contrast, there has been comparatively less work into the genetic drivers of MS 
clinical course. The large GWAS have shown no significant loci that differentiate 
progressive-onset from bout-onset MS, even in cohorts enriched for progressive cases(7). 
Similarly no association has been found with disability(4, 5, 8, 9).This likely reflects the 
comparative difficulty in evaluating clinical course in genetic studies, since MS clinical 
course (conversion to active disease, relapse, or disability progression) is not easily studied by 
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GWAS, as GWAS are cross-sectional or case-control in design. While MS clinical course is 
best assessed longitudinally, and ideally in real time and from disease onset, so as to reduce 
potential impacts of reverse causality or heterogeneity by treatment or other disease aspects.  
 
A more expeditious approach to assess genetic determinants of clinical course is to utilise 
established GWAS determined MS onset associated variants, and evaluate these as predictors 
of MS clinical course in a prospective longitudinal cohort study. As we can hypothesize that 
those genetic variants associated with MS onset are potentially also involved in clinical 
course. This brings to bear the strengths of this study design, while mitigating the power 
limitations attendant to using a genome-wide approach.  
 
Using this approach we have shown in a well-described longitudinal cohort of established MS 
cases, we have shown some evidence that known MS risk SNPs influence relapse and 
disability.(10) Here we extend this approach to analyse data from a prospective cohort of 
cases recruited around their first clinical episode suggestive of CNS inflammatory 
demyelination referred to as a first demyelinating event (FDE), and followed for five years 
with repeated neurological review. All measures of MS clinical course have been collected 
prospectively, including conversion to MS, relapse and measures of disability.  
2.3 Methods 
 
Study design 
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The Ausimmune case-control study(11), was designed to elucidate environmental and genetic 
risk factors for the onset and early progression of MS. The Ausimmune Study recruited a 
study sample of 282 case participants with a first clinical diagnosis of CNS demyelination 
indicating a high risk of developing MS. Case participants in the Ausimmune Study have 
been followed up in the AusLong cohort Study; (the analyses presented here) includeing 
follow-up to five years from study recruitment (84.6% retention).  
 
The AusLong Study cohort included in these analyses is slightly different to the original 
Ausimmune Study case participant sample, as a result of clinical information provided up to 
the 5-year review. Three Ausimmune Study case participants were identified as not having 
had a MS-associated FDE (one neuromyelitis optica, one Susac’s Syndrome, and one pineal 
germinoma). Additionally, 3 cases originally regarded as bout-onset were reclassified as 
being progressive-onset after follow-up.  
The Ausimmune Study and AusLong Study were approved by nine regional Human Research 
Ethics Committees. All participants gave written informed consent. 
2.4 Measurement of clinical outcomes  
Several clinical outcomes were evaluated, including time to conversion to clinically definite 
MS (CDMS), number of relapses, and annualised disability progression from FDE to five 
year review (average 5.8 years from onset). Conversion to MS was defined primarily as the 
occurrence of two or more clinical demyelinating episodes, thus satisfying the diagnostic 
requirements of dissemination in space and time, or a single episode plus paraclinical 
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evidence, as per the 2005 McDonald criteria(12) (a minority of cases were diagnosed 
following MRI (either at the 2/3-year or 5-year reviews) based on this latter criterion (n=20)). 
Conversion to MS was reported at annual review and cross-checked with neurological 
records. A relapse was defined according to the 2001 McDonald Criteria(13) as the acute or 
subacute appearance or reappearance of a neurological abnormality (lasting at least 24 hours) 
in the absence of other potential explanatory factors. Relapses were reported at annual review 
and only relapses which were diagnosed and verified by a neurologist were included in this 
analysis. Disability was assessed by the Kurtzke Expanded Disability Status Scale 
(EDSS)(14) assessed at the 5-year review by the study neurologists. 
2.5  Genotyping and SNP selection 
 
DNA from AusLong participants was genotyped using the Illumina Human Exome BeadChip 
(Illumina Human Exome-12 v1.2 array) which includes ~244,000 exome SNPs with an 
additional ~87,000 MS relevant variants added as a customised component. Quality 
control(15) was conducted based on previous protocols. In general, individuals were excluded 
based on the following criteria: a call rate of <99%, gender error or duplicate discordance. 
Variants were excluded on the basis of a call rate of <99% or a deviation from Hardy-
Weinberg equilibrium with P<1.0x10-6. Principal components analysis was carried out to 
identify population outliers(16). Data on the previously published 110 MS-associated non-
HLA region SNPs(1, 2, 7) and 6 HLA SNPs(2, 3, 17) were extracted for analysis.  
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2.6  Data analysis 
 
Predictors of time to conversion to MS and to relapse were evaluated by Cox proportional 
hazards regression models, the latter for repeated events using the gap-time model by 
Prentice(18). All covariates satisfied the proportional hazards assumption.  
 
Annualised change in EDSS (ΔEDSS) was calculated by taking the 5-year review EDSS and 
dividing by the duration between the day before the date of the FDE (EDSS assumed to be 0) 
and the 5-year review; this proportion was rendered into an annualised value. Predictors of 
ΔEDSS were evaluated using linear regression, adjusted for whether persons were having a 
relapse at the time of their 5-year EDSS assessment. Because the annualised change in 
disability was highly skewed, a log-transformation was applied to satisfy linear regression 
assumptions of minimal heteroskedasticity. All means and coefficients, however, were back-
transformed and presented on the original scale of ΔEDSS. Adjustment for Bonferroni 
multiple comparison was applied for 116 SNPs (110 non-HLA and 6 HLA), this defined as 
the as-measured p-value multiplied by the number of tests (n=116)(19).  
 
We created a cumulative genetic risk score (CGRS) which included the significant SNPs from 
the MS/relapse analysis and the ΔEDSS analysis separately. The common disease-common 
variant hypothesis predicts that common disease-causing alleles, or variants, will be found in 
all human populations which manifest a given disease. So we wanted to see how these 
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common variants predicted MS relapse and disability progression. We created two variables 
that provided values for the number of risk genotypes affecting outcomes, to represent two 
cumulative genetic risk scores(20-22). For example, those subjects with three, four or five 
genotypes that associated with higher probability of conversion to MS were each compared 
with the reference group – those carrying fewer than two associated SNPs. Where only the 
homozygous level of the risk genotype was significantly associated with outcomes, this was 
defined as the risk genotype, but where both the heterozygote and homozygote carriers of the 
risk genotypes were significantly associated with outcomes, these were defined as the risk 
genotypes.  
 
To assess potential type 1 error and provide additional evidence to support that our findings 
did reflect altered risk of the outcome, we undertook a simulation involving the 14 SNPs 
found to significantly predict CDMS/relapse and disability progression (7 for CDMS/relapse, 
7 for disability progression). For this analysis, a permutation simulation was done wherein 
AusLong participants’ genotype data for these SNPs was randomly reallocated in equivalent 
proportions of genotype to that in the original sample. For example, the proportions of 
genotype rs842639 were such that 125 persons had the reference genotype and the remainder 
the non-reference genotype (Table 3). The simulated genotypes were generated, analysed and 
the magnitudes of the estimates resultant therefrom retained. These simulations were run 
50,000 times and the proportion of magnitudes resulting that were as or more extreme than 
that found in the as-measured analyses denoted the significance for each SNP. 
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While the total study sample was 279 participants, the analyses in this paper are restricted to 
the 127 cases with a classic FDE and genotyping data for CDMS/relapse and 125 cases for 
disability progression. Additionally, 23 of the cases had PPMS.  
 
All statistical analyses above were conducted in Stata/SE 12.1 (StataCorp LP, College 
Station, Texas, USA).  
2.7 Results 
Characteristics of participants 
Of the 279 participants in the AusLong Study, genotype data were available for 207 
participants; 127 of these had a classic FDE and were evaluated in our analyses. Of these, 98 
(77.2%) were female and the mean age at study entry was 37.8 (SD: 9.5) years. 68 (53.5%) 
had converted to CDMS by 5-year review and had 151 relapses, while the median 5-year 
EDSS was 1 (interquartile range: 0-2). Of the 207 cases, 125 participants had an EDSS 
recorded at 5 years.  
 
Non-HLA SNP predictors of clinical outcomes 
We identified five non-HLA SNPs which predicted conversion to MS, while four non-HLA 
SNPs predicted relapse (Table 1). Two SNPs (rs1021156 near PKIA and ZC2HC1A, 
rs12599600 near PRM1 and RMI2) were associated with both CDMS and relapse. None of the 
SNPs which predicted conversion to MS and/or relapse showed any association with ΔEDSS. 
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While none of these associations persisted in significance on adjustment for multiple 
comparisons (116 tests), the consistent effect direction between conversion to MS and relapse, 
even for those SNPs that did not significantly associated with the other outcome, increases 
our confidence that the associations are genuine.  
Table 1 Seven top non HLA-SNPs and their associations with the hazard of  conversion to MS  and relapse* 
SNP Chr Gene$ MS Relapse 
   Number of 
CDMS (%) 
HR (95% CI) Number of 
Relapses (%) 
HR (95% CI) 
rs12599600# 
CC^ 
CA+AA 
Trend: 
16 RMI2, 
PRM1 
 
43 (63.24) 
25 (36.76) 
 
 
1.00 [Reference] 
0.41 (0.24, 0.70) 
p=0.001 
 
107 (70.86) 
44 (29.14) 
 
 
1.00 [Reference] 
0.54 (0.34, 0.87) 
p=0.011 
rs1021156 
CC 
CT^ 
TT^ 
Trend: 
8 ZC2HC1A, 
PKIA 
 
33 (48.53) 
28 (41.18) 
7 (10.29) 
 
1.00 [Reference] 
1.44 (0.86, 2.42) 
3.56 (1.96, 6.48) 
p=0.003 
 
69 (45.70) 
59 (39.07) 
23 (15.23) 
 
1.00 [Reference] 
1.22 (0.77, 1.95) 
2.41 (1.46, 3.97) 
p=0.015 
rs694739 
AA^ 
AG 
GG 
Trend: 
11 PRDX5, 
CCDC88B 
 
31 (45.59) 
32 (47.06) 
5 (7.35) 
 
1.00 [Reference] 
0.69 (0.41, 1.18) 
0.34 (0.14, 0.83) 
p=0.012 
 
69 (45.70) 
66 (43.71) 
16 (10.60) 
 
1.00 [Reference] 
0.78 (0.51, 1.19) 
0.71 (0.29, 1.76) 
p=0.31 
rs802734 
AA 
AG 
GG^ 
Trend: 
6 PTPRK , 
THEMIS 
 
31 (45.59) 
25 (36.76) 
12 (17.65) 
 
1.00 [Reference] 
0.89 (0.52, 1.51) 
3.97 (1.83, 8.62) 
p=0.034 
 
72 (47.68) 
49 (32.45) 
30 (19.87) 
 
1.00 [Reference] 
0.78 (0.47, 1.28) 
1.61 (0.96, 2.69) 
p=0.42 
rs1359062# 
AA 
AG^+GG^ 
Trend: 
1 RGS1,  
RGS21 
 
41 (60.29) 
27 (39.71) 
 
 
1.00 [Reference] 
1.71 (1.03, 2.84) 
p=0.039 
 
88 (58.28) 
63 (41.72) 
 
 
1.00 [Reference] 
1.41 (0.91, 2.20) 
p=0.13 
rs35929052# 
CC^ 
CT+TT 
Trend: 
16 IRF8, 
LOC146513 
 
57 (83.82) 
11 (16.18) 
 
 
1.00 [Reference] 
0.83 (0.45, 1.54) 
p=0.55 
 
137 (90.73) 
14 (9.27) 
 
 
1.00 [Reference] 
0.49 (0.30, 0.79) 
p=0.003 
rs62023605# 
AA 
AC^+CC^ 
Trend: 
16 CLEC16A, 
SOCS1 
 
39 (57.35) 
29 (42.65 ) 
 
 
1.00 [Reference] 
1.55 (0.94, 2.54) 
p=0.08 
 
71 (47.02) 
80 (52.98) 
 
 
1.00 [Reference] 
1.78 (1.18, 2.68) 
p=0.006 
Abbreviations: SNPs: single-nucleotide polymorphisms; CDMS: Clinically definite MS.HR: hazard ratio. 
* adjusted for age, sex, and study recruitment, before adjustment for multiple comparisons. 
$ Provide nearest two genes for intergenic SNPs. 
#The homozygous genotypes were combined with the heterozygous ones due to small numbers. 
^ Risk genotype for cumulative genetic risk score (CGRS). 
Results in bold denote statistically significant results (p<0.05). 
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Combining the seven SNPs that predicted conversion to MS and/or relapse (Table 1) into a cumulative genetic risk score, we found evidence of a significant 
positive association of increasing number of risk genotypes and subsequent hazard of CDMS and relapse (Table 2, Figure 1). While the associations were not 
neatly dose-dependent for CDMS or relapse, these results suggest that an increasing number of risk genotypes is deleterious for subsequent disease activity. 
  
Table 2 Cumulative risk of CDMS and relapse for the seven SNPs associated with conversion to MS and relapse* 
 CDMS p-value Relapse p-value 
 Number of 
CDMS  
HR (95% CI)  Number 
of relapses 
HR (95% CI)  
≤ 2 risk genotypes# 
3 risk genotypes 
4 risk genotypes 
≥ 5 risk genotypes* 
15 
27 
11 
15 
1.00 [Reference] 
3.49 (1.76, 6.92) 
3.35 (1.61, 6.98) 
5.98 (2.98, 12.01) 
 
3.45×10-4 
1.27×10-3 
4.77×10-7 
ptrend=1.41×10-7 
16 
64 
30 
41 
1.00 [Reference] 
3.91 (2.12, 7.27) 
4.51 (2.39, 8.53) 
6.07 (3.26, 11.28) 
 
 
1.65×10-5 
3.44×10-6 
1.22×10-8 
ptrend=9.87×10-9 
# None carried zero risk genotype, three participants carried one risk genotype for CDMS.  
* One participant carried seven risk genotypes for CDMS, five participants carried six risk genotypes for CDMS. 
Results presented are adjusted for age, sex, and study recruitment center (QLD, NSW, VIC, TAS). 
Results in bold denote statistically significant results (p<0.05).  
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Figure 1: Kaplan-Meier survival plot for cumulative genetic risk score of conversion to MS (A) and relapse (B). 
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SNP Predictors of annualised change in disability  
We identified seven non-HLA SNPs (Table 3) that were associated with ΔEDSS; no HLA 
SNPs significantly predicted disability progression. None of these SNPs showed any material 
association with conversion to MS or relapse.  
 
Table 3 Seven top SNPs and their associations with annualized change in disability (ΔEDSS) 
SNP Chr Gene$ ΔEDSS  
   Number of 5-year 
disability measures (%) 
β (95%CI) 
rs7588193#  
AA 
AG^+GG^ 
Trend: 
2 ZFP36L2 , 
HAAO 
 
 
74 (59.20) 
51 (40.80) 
 
 
0.27 (0.22, 0.32) 
+0.12 (0.04, 0.21) 
p=0.005 
rs842639 
AA^ 
AG 
GG 
Trend: 
2 FLJ16341  
61 (48.80) 
48 (38.40) 
16 (12.80) 
 
0.36 (0.30, 0.42) 
-0.03 (-0.12, 0.06) 
-0.20 (-0.32, -0.08) 
p=0.007 
rs35967351 
AA^ 
AT 
TT 
Trend: 
1 SLAMF7  
60 (48.00) 
54 (43.20) 
11 (8.80) 
 
0.38 (0.32, 0.44) 
-0.10 (-0.19, -0.02) 
-0.14 (-0.29, 0.01) 
p=0.011 
rs2283792 
CC^ 
CA 
AA 
Trend: 
22 MAPK1  
27 (21.60) 
64 (51.20) 
34 (27.20) 
 
0.43 (0.33, 0.53) 
-0.12 (-0.24, -0.01) 
-0.17 (-0.29, -0.04) 
p=0.013 
rs3825568 
GG 
GA^ 
AA^ 
Trend: 
14 ZFP36L1  
33 (27.05) 
59 (48.36) 
30 (24.59) 
 
0.26 (0.18, 0.34) 
+0.06 (-0.04, 0.16) 
+0.15 (0.03, 0.27) 
p=0.016 
rs2546890 
AA 
AG^ 
GG^ 
Trend: 
5 LOC285626  
46 (36.80) 
52 (41.60) 
27 (21.60) 
 
0.26 (0.19, 0.32) 
+0.09 (-0.01, 0.19) 
+0.12 (0.01, 0.24) 
p=0.030 
rs8070345 
GG 
GA^ 
AA^ 
Trend: 
17 VMP1  
32 (25.60) 
61 (48.80) 
32 (25.60) 
 
0.26 (0.18, 0.34) 
+0.06 (-0.05, 0.16) 
+0.12 (0.0009, 0.24) 
p=0.047 
Abbreviations: SNPs: single-nucleotide polymorphisms; CDMS: Clinically definite MS.HR: 
hazard ratio; EDSS: Expanded Disability Status Scale. ΔEDSS: Annualised disability progression 
from FDE to 5-year review. 
* adjusted for age, sex, study recruitment center and whether participants were having a relapse at 
the time of their 5-year disability measurement, before adjustment for multiple comparisons. 
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$ Provide nearest two genes for intergenic SNPs. 
#The homozygous genotypes were combined with the heterozygous ones due to small numbers. 
^ Risk genotype for cumulative genetic risk score (CGRS). 
Disability results presented as geometric mean ΔEDSS (95% CI) for the reference group, while 
coefficient relative to reference (β (95% CI)) are presented for subsequent levels. 
Results in boldface denote statistically significant results (p<0.05). 
 
For the seven disability-associated SNPs, where the risk genotype was the genotype 
associated with an increase in EDSS and not necessarily the minor allele, we found a strong 
and significant dose-response (Table 4, Figure 2). For example compared to those with ≤2 
risk genotypes, those with ≥6 risk genotypes had an annual disability progression rate of 
nearly 0.5 EDSS points greater, which over five years equates to 2.5 EDSS points. The CGRS 
model explained 32.7% of the variance in disability progression (R2=0.327, Ptrend=1.53×10-9).  
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Table 4 Cumulative risk of disability for the seven SNPs that predicted ΔEDSS  
 Number of 5-year disability measures β (95%CI) p-value R2 
≤ 2 risk genotypes# 
3 risk genotypes 
4 risk genotypes 
5 risk genotypes 
≥ 6 risk genotypes* 
21 
39 
29 
26 
10 
 
0.14 (0.07, 0.22) 
+0.12 (0.02, 0.22) 
+0.20 (0.09, 0.31) 
+0.28 (0.17, 0.40) 
+0.48 (0.30, 0.66) 
 
 
0.024 
6.80x10-4 
5.14×10-6 
8.36×10-8 
ptrend=1.53×10-9 
0.327 
# No participants carried zero risk genotypes, five participants carried one risk genotypes, sixteen carried two risk genotypes. 
* No participants carried seven risk genotypes, ten participants carried 6 risk genotypes.  
p: adjusted for age, sex, and study recruitment centre; ΔEDSS: annualised change in EDSS. 
Disability results presented as geometric mean ΔEDSS (95% CI) for the reference group, and coefficient relative to the reference (β (95% CI)) for 
subsequent levels. 
Results in bold denote statistically significant results (p<0.05). 
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Figure 2: The line plot of cumulative genetic risk score predicting ΔEDSS. Results presented as geometric mean ΔEDSS and 95% CI.  
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HLA SNP predictors of MS clinical course 
In addition to the 110 non-HLA MS-risk associated SNPs, we also examined the association of six HLA SNPs which have been associated with MS risk. 
These results show that only two of these were associated with the hazard of CDMS and relapse, but not disability, while the prototypical HLA MS-risk 
associated loci, DRB1*1501, was not significantly associated with any clinical outcomes in this study (Table 5).  
 
 
Table 5 The association between three HLA SNPs and MS clinical course* 
SNP HLA allele or SNP CDMS Relapse ΔEDSS 
  Number of 
CDMS (%) 
HR (95% CI) Number of 
relapse (%) 
HR (95% CI) Number of 5-year 
disability measures (%) 
β(95%CI) 
rs9266773$ 
AA 
AG 
Trend: 
B*44:02  
60 (88.24) 
8 (11.76) 
 
1.00 [Reference] 
0.44 (0.20, 0.97) 
p=0.043 
 
142(94.04) 
9 (5.96) 
 
1.00 [Reference] 
0.37 (0.19, 0.71) 
p=0.003 
 
110 (88.00) 
15 (12.00) 
 
-0.86 (-0.93,-0.80) 
-0.04 (-0.19, 0.10) 
p=0.62 
rs9277561# 
AA 
AG+GG 
Trend: 
rs9277565[T]  
43 (64.18) 
24 (35.82) 
 
 
1.00 [Reference] 
1.08 (0.64, 1.84) 
p=0.77 
 
78 (52.35) 
71 (47.65) 
 
 
1.00 [Reference] 
1.59 (1.04, 2.43) 
p=0.033 
 
76 (61.79) 
47 (38.21) 
 
-0.89 (-0.96,-0.82) 
+0.04 (-0.10, 0.18) 
p=0.54 
rs3135391# 
GG 
GA+AA 
Trend: 
DRB1*15:01  
25 (36.76) 
43 (63.24) 
 
 
1.00 [Reference] 
1.63 (0.97, 2.73) 
p=0.067 
 
50(33.11) 
101(66.89) 
 
 
1.00 [Reference] 
1. 30 (0.82, 2.06) 
p=0.26 
 
54 (43.20) 
71 (56.80) 
 
-0.80 (-0.94,-0.65) 
-0.11 (-0.27, 0.05) 
p=0.12 
Abbreviations: SNPs: single-nucleotide polymorphisms; HR: hazard ratio; EDSS: Expanded Disability Status Scale; ΔEDSS: Annualised disability 
progression from FDE to 5-year review. 
* adjusted for age, sex, and study recruitment, before adjustment for multiple comparisons. 
CDMS: Clinically definite MS, FDE: First demyelinating event. 
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$ No persons had the GG genotype. 
#The homozygous genotypes were combined with the heterozygous ones due to small numbers. 
Disability results presented as geometric mean ΔEDSS (95% CI) for the reference group, while coefficient relative to reference (β (95% CI)) are 
presented for subsequent levels. 
Results in boldface denote significant results (p<0.05). 
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2.8 Discussion 
 
Using a longitudinal cohort of participants with a first neurological presentation of symptoms 
suggestive of CNS demyelination, we investigated whether known MS susceptibility SNPs 
were associated with MS clinical course and disability progression in early disease. We found 
that several known MS risk-associated SNPs influenced MS clinical course, including 7 SNPs 
which predicted the hazard of CDMS and/or relapse and 7 other SNPs which predicted 
ΔEDSS. There is a greater chance that SNPS found in both the relapse and conversion to MS 
analyses are more likely to be real findings than those found in either analysis alone as these 2 
measures (relapse and conversion to MS) measure the same parameter but in different ways. 
While none of these SNPs individually remained significant after adjusting for multiple 
comparisons, epidemiological supports such as dose-dependency and internal consistency 
between related clinical outcomes supported the validity of taking these SNPs forward to a 
CGRS assessment. The CGRS analysis showed that, in combination, a greater number of risk 
genotypes had a highly positive association with conversion to MS (HR 5.98 for ≥ 5 risk 
genotypes vs ≤ 2 risk genotypes), relapse (HR 6.07 for ≥ 5 risk genotypes vs ≤ 2 risk 
genotypes), and ΔEDSS where change in EDSS for those who had ≥ 6 risk genotypes was 
0.48 EDSS points per year greater than reference.  
 
Our CGRS model for disability progression explained 32.7% of the variance in MS disability 
progression within this dataset. These results suggest that these seven common variants in 
combination significantly contribute to disability progression of multiple sclerosis.  
 
The risk variants detected were completely different between disability and CDMS/relapse. 
Hence, we hypothesised that CDMS/relapse and disability progression may be driven by 
different genetic pathways, with CDMS and relapse driven by central nervous system 
inflammation, whereas disability progression may be more driven by neurodegeneration. 
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Previous work has suggested that the two processes may be independent(23), although this is 
controversial. The lack of overlap between genetic variants that may drive conversion and 
relapse and those associated with disability progression is of great interest and may add 
support to the argument that these two processes may be independent and require different 
approaches to treatment. 
One interesting observation in our study was that the effects on MS clinical course of the 
HLA SNPS that have such significant effects on MS risk was varied, with only HLA-B*44:02 
(rs9266773) having a significant protective association with relapse and conversion to MS, 
the latter reaching statistical significance on permutation testing after correction for multiple 
testing. The MS risk allele of HLA DRB1*15:01 was not clearly associated with MS clinical 
course in this study, supporting findings from some but not all previous studies(2, 10). We did 
not find that HLA DRB1*1501 was associated with MS clinical course and the HLA B*44:02 
proxy SNP was not significantly associated with any element of MS clinical course, thus 
supporting findings from other studies(2). It is reasonable to assume that, while some risk-
associated SNPs are also associated with MS clinical course, others may only predict onset.  
 
We have shown some overlap with our previous study in established MS that further validates 
this work. In particular, the MS risk SNP near the RGS1 gene associated with the hazard of 
CDMS in the current analysis was significantly associated with subsequent relapse risk in our 
previous study(10).  
 
Basing results only on statistical significance in a longitudinal MS study when looking at 
multiple genetic markers is difficult and requires large sample sizes. The major limitation of 
our study is the small sample size, particularly when this is further reduced by restriction to 
only those with genotyping data and those with initial bout-onset disease with onset close to 
the time of study entry. Therefore, in our study, we have also used several other 
epidemiological concepts to provide support for our results, including dose-dependency of 
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allelic effect, internal consistency between related outcome measures (CDMS and relapse), 
and external consistency of directionality with associations found previously, as well as 
cumulative genetic risk scores. All 7 SNPs that were associated with CDMS and relapse risk, 
had significant allele dose responses, and all effects were in the same direction for the hazard 
of CDMS and relapse and in the same direction as for MS risk in GWAS providing support 
for their significance. These seven SNPs may be near genes that have significant effects on 
MS clinical course and warrant further investigation.  
 
A key strength of our study is its long follow-up, beginning at the first presentation of 
symptoms of disease and continuing for now 10 years from onset. This allows confidence that 
the clinical course parameters measured are accurate, particularly for disability progression. 
Large GWAS analyses, while benefiting from a large sample size allowing for the ability to 
adjust for multiple comparisons, are methodologically limited by their inability to do more 
than compare groups, or measure progression using cross-sectional measures, rather than 
using time-to-event prospective analyses of clinical course that we have used in the present 
study. In this study, we have utilised the study strengths of a prospective cohort study design 
and evaluated the known MS risk-associated SNPs as predictors of clinical course. In this 
fashion, we retain the methodological strengths of the study design, the accuracy of 
prospective clinical course monitoring, and the reduction of reverse causality, while not 
having the statistical limitations of trying to evaluate using a genome-wide approach. We 
have utilised this approach previously in our cohort of established MS (average disease 
duration 12 years). However, that study was undertaken in a cohort that experienced little 
disability progression over a mean follow-up of 2.3 years and was in a largely treated 
population with a low annual relapse rate. The present study makes use of a cohort followed 
essentially from symptom onset and who accordingly were not on disease-modifying therapy 
or yet suffering appreciable impacts of disease. As relapsing-remitting MS patients have a 
highly variable time interval between the first and the second episode of central nervous 
Chapter2: Known multiple sclerosis genetic susceptibility variants are associated with clinical 
course: a cohort study 
 
 61 
system (CNS) demyelination which clinically or radiologically defines the onset of 
CDMS(24).Understanding the genetic determinants of this temporal window of disease 
clinical course is important as this could allow appropriate counselling, open new avenues for 
drug development, and allow better selection from the available treatment options. Even so, 
our results should be replicated in other longitudinal cohorts to allow greater confidence in 
their veracity.  
 
In conclusion, our findings support an association between known MS risk genes and MS 
clinical course. These data support a role for genetic factors in MS progression and suggest 
that the genetic drivers of MS progression are polygenic. These results require validation in 
other cohorts, but, with replication these loci may serve as potential targets for further 
translational research. 
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Chapter 3. Conclusion  
3.1 On the role of risk-associated genetic loci in modulating clinical course in 
multiple sclerosis. 
 
In multiple sclerosis (MS), patients generally present with a first clinical episode of 
demyelination (FDE) which has an uncertain prognosis with few generalizable markers of 
subsequent disease severity. Following an FDE there are no clear genetic indicators of future 
conversion to MS (CDMS), risk of relapse, or rate of disability accumulation, hampering the 
effort to providing early intervention to those patients at high risk.  
 
We therefore, developed an a priori hypothesis that 116 MS-risk associated genetic single 
nucleotide polymorphisms (SNPs) may also significantly affect MS clinical outcomes. 
Utilising a longitudinal cohort study of persons who have had a FDE, followed for 5-years, 
we found that: 
 Seven non-HLA SNPs predicted relapse and/or CDMS, and seven other non-
HLA SNPs predicted the annualised change in disability status (ΔEDSS, as 
measured by Expanded Disability Status Scale) 
 We generated genetic risk score (CGRS) based on those identified risk SNPs, 
which significantly predicted CDMS and relapse in a significant, dose-dependent 
manner: patients having >5 risk genotypes had a 6-fold greater risk of CDMS 
and relapse compared to those with <2; those carrying ≥6 risk genotypes 
progressed at 0.48 EDSS points per year faster compared to those with <2, and 
the CGRS model explained 32% of the variance in disability. 
For the first time, we demonstrated that MS genetic susceptibility SNPs predicted worse MS 
clinical course in three key metrics. These results, if replicated, may aid in developing 
prognostic algorithms in the early disease period in MS and provide further mechanistic 
insights. We believe these findings will be of benefit for MS patients.  
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The candidate-gene approach and GWAS have been the two major methods for genetic 
research. Linkage studies based on family data have been useful in examining the effect of 
specific genes associated with Mendelian (i.e. monogenic) diseases, but it has been less 
effective in identifying susceptibility genes of polygenic complex disease such as MS. 
Likewise, the candidate-gene approach has usually been unsuccessful in identifying novel loci 
in MS genetic research. Whereas GWAS is more useful and effective to search MS 
susceptibility genes. Thus, it enhances the chance to identify MS clinical course associated 
variants by utilising candidate gene which identified by GWAS in our longitudinal cohort 
study. 
 
3.2 Major Contributions 
 
My research’s major contributions can be listed as follows: 
 Using one of the largest longitudinal studies of early-MS clinical course, we present 
evidence that the cumulative effects MS susceptibility genes significantly modulate 
MS clinical course. 
 These data strongly support a role for genetic factors in MS progression and strongly 
suggest that the genetic drivers of MS progression are polygenic.  
 These loci may serve as potential targets for further translational research. 
3.3 Future directions and challenge 
 
The AusLong study cohort has huge environmental, genetic and clinical data, including 
conversion to clinically definite MS (CDMS) and occurrence of relapse derived from annual 
review and medical records, while EDSS was measured at 5-year review. Our research group 
has collected extant environmental and clinical data on these participants over the last 9-10 
years. The 10-year review data collection will be finished soon, future analysis utilising these 
data can be listed as follows: 
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 Clinical application: Translational medicine - translating predictive factors to clinical 
application. For genetics, this means potentially utilising genetic testing of at-risk 
patients to identify their potential future risk of disease (e.g. offspring/relatives of 
existing cases) or gauging prognosis in persons presenting with symptoms suggestive 
of the disease. 
 Biological mechanisms: having substantiated some MS-risk associated SNPs in MS 
clinical course, now it remains to identify the mode by which these manifest in 
disease and impact on disease severity. For some genes this is more evident, but SNPs 
in intergenic regions will require investigation.  
 Identify other potential polymorphism targets, gene coding functions and epigenetic 
regulation: For genes, it means using rare variants (minor allele frequencies 
(MAF<5%)) exome chips in large sample size to find new rare polymorphism targets 
which associated with MS onset and clinical course. For gene coding experiment, it is 
necessary to identify how these risk variants impair or change the function of the 
resulting proteins and how these changed proteins influence MS onset and clinical 
course. With the development of epigenetic, it’s possible to utilize methylation 
analysis such as genome-wide methylation profiling to identify and understand the 
functional mechanisms at work in MS (both MS onset and processes). 
Up to the present, major progress has been made in identifying multiple sclerosis 
susceptibility genes. However, research in genetic modulators of clinical course and disease 
severity are comparatively limited. While this may partly reflect the inherent complexity of 
the condition, it may also reflect the need for different study designs that more effectively 
measure disease-related events and disability accumulation, while at the same time balancing 
against the logistical barriers attendant to this type of follow-up. Therefore, the new discovery 
will depend on recruiting large cohorts, while maintaining comprehensive databases of 
environmental/behavioural, genetic and clinical information, and potentially utilising novel 
genetic technologies and statistical models. For instance, using new exome chips which focus 
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on the rare variants and well-measured phenotypes such as CDMS, relapse, disability, and 
brain atrophy (identified by MRI). Further research into these MS susceptibility genes may 
lead to a greater understanding of multiple sclerosis susceptibility & pathogenesis, and to a 
more personalised treatment approach.   
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Appendix 1. List of 110 known non-HLA MS risk variants  
Chr rsID Position RAF RA OR (95% CI) P-value Gene Function 
1 rs3748817 2525665 0.64 A 1.14 (1.10-1.18) 1.33E-12 MMEL1 intronic 
1 rs3007421 6530189 0.12 A 1.12 (1.07-1.18) 9.61E-07 PLEKHG5 intronic 
1 rs12087340 85746993 0.09 A 1.22 (1.15-1.29) 5.13E-12 BCL10 (dist=4406), DDAH1 (dist=37175) intergenic 
1 rs11587876 85915183 0.79 A 1.12 (1.07-1.17) 8.40E-08 DDAH1 intronic 
1 rs41286801 92975464 0.14 A 1.20 (1.15-1.25) 7.92E-16 EVI5 UTR3 
1 rs7552544 101240893 0.56 A 1.08 (1.05-1.12) 3.67E-06 VCAM1 (dist=36292), EXTL2 (dist=97035) intergenic 
1 rs11581062 101407519 0.29 G 1.05 (1.01-1.09) 1.20E-02 VCAM1 intronic 
1 rs6677309 117080166 0.88 A 1.34 (1.27-1.41) 1.45E-28 CD58 intronic 
1 rs666930 120258970 0.53 G 1.09 (1.06-1.13) 7.49E-08 PHGDH intronic 
1 rs2050568 157770241 0.53 G 1.08 (1.05-1.12) 1.33E-06 FCRL1 intronic 
1 rs35967351 160711804 0.67 A 1.09 (1.05-1.13) 1.70E-06 SLAMF7 intronic 
1 rs1359062 192541472 0.82 C 1.18 (1.13-1.23) 1.84E-13 RGS21 (dist=205058), RGS1 (dist=3385) intergenic 
1 rs55838263 200874728 0.71 A 1.12 (1.08-1.17) 1.41E-09 C1orf106 intronic 
2 rs4665719 25017860 0.25 G 1.09 (1.05-1.13) 6.80E-06 CENPO intronic 
2 rs2163226 43361256 0.71 A 1.10 (1.07-1.15) 7.02E-08 
HAAO (dist=341505), ZFP36L2 
(dist=88285) 
intergenic 
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2 rs842639 61095245 0.65 A 1.11 (1.08-1.15) 1.70E-09 FLJ16341 ncRNA_intronic 
2 rs7595717 68587477 0.26 A 1.10 (1.06-1.14) 3.29E-07 CNRIP1 (dist=40294), PLEK (dist=4845) intergenic 
2 rs17174870 112665201 0.76 G 1.03 (1.00-1.07) 8.84E-02 MERTK intronic 
2 rs9967792 191974435 0.62 G 1.11 (1.07-1.15) 1.80E-09 STAT4 intronic 
2 rs9989735 231115454 0.18 C 1.17 (1.12-1.22) 7.84E-14 SP140 intronic 
3 rs11719975 18785585 0.27 C 1.09 (1.05-1.13) 5.39E-06 
SATB1 (dist=305320), KCNH8 
(dist=404432) 
intergenic 
3 rs2371108 27757018 0.38 A 1.08 (1.05-1.12) 2.06E-06 EOMES downstream 
3 rs1813375 28078571 0.47 A 1.15 (1.12-1.19) 5.75E-18 
EOMES (dist=314786), CMC1 
(dist=204553) 
intergenic 
3 rs4679081 33013483 0.52 G 1.08 (1.04-1.11) 1.20E-05 CCR4 (dist=17080), GLB1 (dist=24617) intergenic 
3 rs9828629 71530346 0.62 G 1.08 (1.05-1.12) 5.49E-06 FOXP1 intronic 
3 rs2028597 105558837 0.92 G 1.04 (0.98-1.11) 1.79E-01 CBLB intronic 
3 rs1131265 119222456 0.80 C 1.19 (1.14-1.24) 1.97E-15 TIMMDC1 exonic 
3 rs1920296 121543577 0.64 C 1.14 (1.11-1.18) 6.75E-15 IQCB1 intronic 
3 rs2255214 121770539 0.52 C 1.11 (1.08-1.15) 1.72E-10 ILDR1 (dist=29412), CD86 (dist=3670) intergenic 
3 rs9282641 121796768 0.92 G 1.12 (1.05-1.19) 5.86E-04 CD86 UTR5 
3 rs1014486 159691112 0.43 G 1.11 (1.07-1.14) 1.16E-09 
IQCJ-SCHIP1 (dist=75957), IL12A 
(dist=15511) 
intergenic 
4 rs7665090 103551603 0.52 G 1.08 (1.05-1.12) 2.41E-06 NFKB1 (dist=13144), MANBA (dist=1040) intergenic 
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4 rs2726518 106173199 0.55 C 1.09 (1.05-1.13) 1.23E-05 TET2 intronic 
5 rs6881706 35879156 0.72 C 1.12 (1.08-1.16) 4.87E-09 IL7R (dist=2233), CAPSL (dist=25242) intergenic 
5 rs6880778 40399096 0.60 G 1.10 (1.06-1.14) 1.70E-08 
DAB2 (dist=973761), PTGER4 
(dist=280936) 
intergenic 
5 rs71624119 55440730 0.76 G 1.12 (1.08-1.17) 2.70E-09 ANKRD55 intronic 
5 rs756699 133446575 0.87 A 1.12 (1.07-1.18) 2.97E-06 VDAC1 (dist=105751), TCF7 (dist=3827) intergenic 
5 none 141506564 0.61 C 1.07 (1.04-1.11) 5.96E-05 NDFIP1 intronic 
5 rs2546890 158759900 0.52 A 1.06 (1.02-1.09) 6.59E-04 LOC285626 ncRNA_exonic 
5 rs4976646 176788570 0.34 G 1.13 (1.09-1.17) 1.04E-12 RGS14 intronic 
6 rs17119 14719496 0.81 A 1.11 (1.06-1.15) 1.91E-06 
CD83 (dist=582348), JARID2 
(dist=526710) 
intergenic 
6 rs941816 36375304 0.18 G 1.13 (1.08-1.18) 4.47E-09 PXT1 intronic 
6 rs72928038 90976768 0.17 A 1.11 (1.07-1.16) 7.63E-07 BACH2 intronic 
6 rs802734 128278798 0.69 A 1.03 (0.99-1.06) 1.58E-01 
THEMIS (dist=39022), PTPRK 
(dist=11126) 
intergenic 
6 rs11154801 135739355 0.37 A 1.11 (1.07-1.15) 2.35E-09 AHI1 intronic 
6 rs17066096 137452908 0.23 G 1.14 (1.10-1.18) 5.91E-12 
IL20RA (dist=86610), IL22RA2 
(dist=12049) 
intergenic 
6 rs7769192 137962655 0.55 G 1.08 (1.04-1.12) 1.30E-05 
OLIG3 (dist=147124), TNFAIP3 
(dist=225670) 
intergenic 
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6 rs67297943 138244816 0.78 A 1.12 (1.07-1.16) 4.83E-08 
TNFAIP3 (dist=40367), PERP 
(dist=164826) 
intergenic 
6 rs212405 159470559 0.62 T 1.15 (1.11-1.19) 1.43E-15 
TAGAP (dist=4375), FNDC1 
(dist=119870) 
intergenic 
7 rs1843938 3113034 0.44 A 1.08 (1.05-1.12) 2.21E-06 
CARD11 (dist=29525), SDK1 
(dist=228046) 
intergenic 
7 rs706015 27014988 0.18 C 1.14 (1.09-1.19) 1.29E-09 
SKAP2 (dist=110647), HOXA1 
(dist=117626) 
intergenic 
7 rs917116 28172739 0.20 C 1.12 (1.07-1.16) 2.07E-08 JAZF1 intronic 
7 rs60600003 37382465 0.10 C 1.16 (1.10-1.22) 2.53E-08 ELMO1 intronic 
7 rs201847125 50325567 0.70 G 1.11 (1.07-1.15) 2.91E-08 
C7orf72 (dist=126715), IKZF1 
(dist=18811) 
intergenic 
7 rs354033 149289464 0.74 G 1.03 (1.00-1.07) 7.70E-02 ZNF767 ncRNA_intronic 
8 rs1021156 79575804 0.24 A 1.12 (1.08-1.16) 5.60E-10 PKIA (dist=58302), ZC2HC1A (dist=2478) intergenic 
8 rs2456449 128192981 0.36 G 1.10 (1.06-1.14) 2.21E-08 
PCAT1 (dist=159722), POU5F1B 
(dist=234876) 
intergenic 
8 rs4410871 128815029 0.72 G 1.12 (1.08-1.16) 1.98E-09 MIR1204(dist=6755),PVT1(dist=87845) intergenic 
8 rs759648 129158945 0.31 C 1.09 (1.05-1.13) 2.82E-06 PVT1 (dist=45446), MIR1208 (dist=3417) intergenic 
9 rs2150702 5893861 0.49 G 1.16 (1.10-1.22) 3.30E-08 MLANA intronic 
10 rs2104286 6099045 0.72 A 1.21 (1.16-1.26) 7.61E-23 IL2RA intronic 
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10 rs793108 31415106 0.50 A 1.09 (1.06-1.13) 5.61E-08 
ZNF438 (dist=94240), ZEB1-AS1 
(dist=190351) 
intergenic 
10 rs2688608 75658349 0.55 A 1.07 (1.03-1.10) 6.37E-05 
CAMK2G (dist=24000), C10orf55 
(dist=11378) 
intergenic 
10 rs1782645 81048611 0.43 A 1.09 (1.05-1.13) 4.30E-07 ZMIZ1 intronic 
10 rs7923837 94481917 0.61 G 1.11 (1.07-1.14) 4.58E-09 
HHEX (dist=26509), EXOC6 
(dist=112553) 
intergenic 
11 rs7120737 47702395 0.15 G 1.13 (1.08-1.18) 7.61E-08 AGBL2 intronic 
11 rs34383631 60793330 0.40 A 1.11 (1.07-1.15) 5.69E-10 CD6 (dist=5482), CD5 (dist=76600) intergenic 
11 rs694739 64097233 0.62 A 1.08 (1.04-1.11) 1.30E-05 
PRDX5 (dist=7938), CCDC88B 
(dist=10457) 
intergenic 
11 rs533646 118566746 0.68 G 1.10 (1.06-1.14) 3.60E-07 TREH (dist=16365), DDX6 (dist=51727) intergenic 
11 rs9736016 118724894 0.63 T 1.10 (1.07-1.14) 2.20E-08 DDX6 (dist=62922), CXCR5 (dist=29581) intergenic 
11 rs523604 118755738 0.53 A 1.09 (1.05-1.13) 2.50E-07 CXCR5 intronic 
12 rs1800693 6440009 0.40 G 1.14 (1.11-1.18) 6.92E-16 TNFRSF1A intronic 
12 rs12296430 6503500 0.19 C 1.14 (1.09-1.18) 3.62E-10 LTBR (dist=2768), CD27-AS1 (dist=44667) intergenic 
12 rs11052877 9905690 0.36 G 1.10 (1.07-1.14) 5.37E-09 CD69 UTR3 
12 rs201202118 58182062 0.67 A 1.14 (1.10-1.18) 7.40E-13 TSFM intronic 
12 rs7132277 123593382 0.19 A 1.10 (1.06-1.15) 1.88E-06 PITPNM2 intronic 
13 rs4772201 100086259 0.82 A 1.12 (1.07-1.17) 1.67E-07 
MIR548AN (dist=27705), TM9SF2 
(dist=67469) 
intergenic 
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14 rs2236262 69261472 0.50 A 1.08 (1.04-1.11) 1.16E-05 ZFP36L1 intronic 
14 rs4903324 75961511 0.19 A 1.10 (1.05-1.14) 9.62E-06 JDP2 (dist=22107), BATF (dist=27273) intergenic 
14 rs74796499 88432328 0.95 C 1.31 (1.21-1.42) 8.47E-11 GALC intronic 
14 rs12148050 103263788 0.35 A 1.08 (1.04-1.11) 1.47E-05 TRAF3 intronic 
15 rs59772922 79207466 0.83 A 1.11 (1.06-1.15) 4.02E-06 
MORF4L1 (dist=17385), CTSH 
(dist=6626) 
intergenic 
15 rs8042861 90977333 0.44 A 1.08 (1.05-1.12) 9.80E-07 IQGAP1 intronic 
16 rs2744148 1073552 0.18 G 1.09 (1.04-1.13) 1.02E-04 
SOX8 (dist=36573), SSTR5-AS1 
(dist=40530) 
intergenic 
16 rs12927355 11194771 0.68 G 1.21 (1.17-1.26) 8.19E-27 CLEC16A intronic 
16 rs4780346 11288806 0.23 A 1.09 (1.05-1.13) 6.80E-06 
CLEC16A (dist=12760), SOCS1 
(dist=59468) 
intergenic 
16 rs6498184 11435990 0.81 G 1.15 (1.10-1.21) 2.07E-10 PRM1 (dist=60798), RMI2 (dist=3321) intergenic 
16 rs7204270 30156963 0.50 G 1.09 (1.06-1.13) 9.32E-08 
MAPK3 (dist=22333), CORO1A 
(dist=37768) 
intergenic 
16 rs1886700 68685905 0.14 A 1.11 (1.06-1.16) 8.76E-06 CDH3 intronic 
16 rs12149527 79110596 0.47 A 1.08 (1.05-1.12) 1.74E-06 WWOX intronic 
16 rs7196953 79649394 0.29 A 1.08 (1.04-1.12) 2.65E-05 
MAF (dist=14772), DYNLRB2 
(dist=925460) 
intergenic 
16 rs35929052 85994484 0.89 G 1.14 (1.09-1.20) 3.32E-07 
IRF8 (dist=38273), LOC146513 
(dist=325553) 
intergenic 
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17 rs12946510 37912377 0.47 A 1.08 (1.04-1.11) 8.51E-06 GRB7 (dist=8839), IKZF3 (dist=1591) intergenic 
17 rs4796791 40530763 0.36 A 1.10 (1.06-1.14) 1.81E-08 STAT3 intronic 
17 rs4794058 45597098 0.50 A 1.07 (1.04-1.11) 1.63E-05 
MRPL45P2 (dist=27112), NPEPPS 
(dist=11346) 
intergenic 
17 rs8070345 57816757 0.45 A 1.14 (1.11-1.18) 5.43E-16 VMP1 intronic 
18 rs7238078 56384192 0.77 A 1.05 (1.02-1.10) 6.29E-03 MALT1 intronic 
19 rs1077667 6668972 0.79 G 1.16 (1.12-1.21) 3.54E-13 TNFSF14 intronic 
19 rs34536443 10463118 0.95 C 1.28 (1.18-1.40) 1.24E-08 TYK2 exonic 
19 rs2288904 10742170 0.77 G 1.14 (1.09-1.19) 9.57E-10 SLC44A2 exonic 
19 rs1870071 16505106 0.29 G 1.12 (1.08-1.16) 5.68E-10 EPS15L1 intronic 
19 rs11554159 18285944 0.73 G 1.15 (1.11-1.20) 2.58E-13 IFI30 exonic 
19 rs8107548 49870643 0.25 G 1.09 (1.05-1.13) 1.98E-06 DKKL1 intronic 
20 rs4810485 44747947 0.25 A 1.08 (1.04-1.12) 1.78E-05 CD40 intronic 
20 rs17785991 48438761 0.35 A 1.09 (1.05-1.13) 6.42E-07 SLC9A8 intronic 
20 rs2248359 52791518 0.60 G 1.07 (1.03-1.10) 9.81E-05 
CYP24A1 (dist=1002), PFDN4 
(dist=32984) 
intergenic 
20 rs2256814 62373983 0.19 A 1.11 (1.07-1.16) 8.34E-07 SLC2A4RG intronic 
20 rs6062314 62409713 0.92 A 1.10 (1.03-1.16) 3.87E-03 ZBTB46 intronic 
22 rs2283792 22131125 0.51 C 1.08 (1.05-1.12) 1.14E-06 MAPK1 intronic 
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22 rs470119 50966914 0.39 A 1.07 (1.03-1.10) 1.51E-04 TYMP intronic 
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association studies (GW AS)(S). However, large GW AS have not found any 
associations between these MS susceptibility genes and MS clinical course. 
Consequently, the potential role of genetic factors in modulating MS clinical course 
remains unclear. In this review, we aim to summarise the findings of MS 
epidemiological and genetic studies and highlight the potential role of both 
environmental and genetic factors in MS onset and progression. Moreover, we outline 
and discuss challenges in thi s research, and the current gaps in our knowledge, 
including biological & clinical implications of genetic risk factors, potential clinical 
phenotype, and epigenetics that might be considered. 
2. Genetic research method 
Linkage and candidate gene method 
Linkage analysis is based on the findings that genes located physically close together 
on a chromosome during the meiosis phase (9). Candidate gene methods are based on 
the knowledge of biological. During the linkage and candidate method period. The 
main findings of this period are HLA II arm area associated with MS onset which 
confi rmed by linkage and candidate gene approach. Based on these fi ndings, linkage 
and candidate gene approach were used to estimate the effect of substantial MS risk 
genes. Linkage analysis is a powerful tool based on the findings that genes located 
physically close together on a chromosome during the meiosis phase(9). Linkage 
analysis became the primary mode of statistical genetic mapping of Mendelian and 
complex diseases with familial aggregation in early diseases genetic research. 
Linkage study based on family data has been useful to examine the effect of specific 
genes associated with Mendelian (i.e., monogenic) diseases, but it has been less 
effective in identifying susceptibility genes for polygenic complex disease such as 
MS. In 2007, the International Multiple Sclerosis Genetics Consortium (IMSGC) 
established the largest non-parametric genome-wide linkage screen in 93 1 MS fami ly 
trios . The important result for this study was identifying the significant linkage within 
the HLA locus, with a peak in the regional logarithm of the odds (LOO) score of 11 .7, 
while none of the loci outside the HLA locus reached statistical significance. Then, 
lots of studies investigating genetic factors involved in MS onset, few susceptibility 
genes were identified. The HLA-DRB1 *15:0l allele had the greatest effect on risk of 
that region area. Generally, given the complexity of MS, and the potential for gene-
environment interaction, linkage and candidate gene studies have not been successful 
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at finding susceptibility loci outside the MHC region in MS. Partly this is because 
these studies are limited by small sample size, as well as the small number of 
candidate variants from previous analyses. In the latter half of the 20 century, linkage 
and candidate analysis was the primary method used for the genetic research of 
Mendelian and complex diseases, which made a large contribution to disease genetic 
research. 
Genome-wide association studies (G WAS) 
Because the limitation of linkage and candidate gene method, genome wide 
association study (OW AS) testing millions of genetic variation marker, the single 
nucleotide polymorphism (SNP), have become the favored genetic mapping method 
of complex disease (10). To increase efficiency and cost, OW AS typically use a 
multistage design. Although OW AS have discovered many SNPs predicting a number 
of conditions ( 11 ), some major challenges have been raised. 
I) Ethnicity or racial mix, referred to as population stratification, is a particular 
kind of confounding. People from different ancestries have a different allele 
frequency in some SNPs( 12). OW AS can be confounded by population 
stratification which can lead to an increasing number of false positive results. 
The way to correct population stratification bias is to measure thi s confounder 
and adjust for it in regression models, or to stratify the case and controls. 
2) Multiple comparisons adjustment. Statistical significance is usually defined 
as p=0.05 in classic epidemiological studies. However, for OW AS, the 
significance threshold must be adjusted to account for the substantial number 
of tests for SNPs. Bonferroni correction is widely used for multiple 
comparison adjustment. The Bonferroni method sets OW AS statistical 
significance at p=0.05/N. However, this method is sometimes considered to be 
too strict a criterion because some tests are not independent. In OW AS, many 
SNPs are in linkage disequilibrium (LD), which means they are correlated. To 
deal with this, the high number of test needs to be replaced. There are two 
common approaches to deal with this problem: 1) to calculate the true number 
of independent tests(l 3); 2) to use the false discovery rate (FDR) method to 
adjust the FDR for an independent test, which has been shown to be effective 
at improving statistical power (14). These methods suggest a genome 
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signi ficant threshold between 10·6 and 10·8, but the classic GWAS threshold of 
10·8 remains widely used. 
The preferable types of studies for MS onset and clinical course research. 
Cross sectional study vs cohort study: a short photo in MS onset 
Cross sectional stud ies are done to investigate whether people have MS onset or MS 
clinical course at a particular time. Cross sectional study looks like a snapshot for MS 
patient. GW AS used cross sectional case-control study design to investigate the 
relationship between the genetic factors and MS onset. Case-control studies (Genome-
wide association study) look backwards. Beginning from an outcome, such as MS 
onset, this type of study works backward in time for genetic factors that might have 
caused the MS. Case-control studies are useful for MS onset that is rare, harmful and 
spends a long time on development, such as MS. There were many biases cannot 
avoid in the case-control study. For instance, reca ll bias, survival bias and 
surveillance bias etc( 15, 16). Additionally, misclassification bias (the wrong diagnose 
of MS) is a problem in the case-control study that relies on a short time diagnosing. 
In recent years, data mining have been used to test big data that proceeds without 
explicit hypotheses. All conclusions just based on the P values of statistica l 
significance. Studies often use convenience samples without think of selection bias 
and other confounder factors can disto11 exposure-outcome associations. In addition, 
the MS clinical course (how the disease behaves o ver time) and long-term outcome of 
MS differs from patient to patient. By contrast, longitud inal cohort study such as 
Ausimmune/AusLong study which fo llowed the progression of MS was more usefu l 
than case control study in MS genetic c linical course research(]?). A longit udinal 
population based coho11 study such as Ausimmune/AusLong study approaches to the 
study of the relationship between genetic and MS cli nical course. These studies have 
specific hypotheses that inform MS clinical data collection and use classical statistic 
model to assess pre-specified genetic fac tors and MS cl inical course phenotype. 
Cohort studies gave a logical sequence from gene tic factors to MS clinical course. 
Hence, these longitudinal cohort study is easie r to understand than a c ross sectional 
case-control study. For Ausimmune/AusLong study, participants with a c lin ical 
diagnosis of a first demyelination episode which indicating a high risk o f developing 
MS need to be recruited. Environmental, behavioural, genetic and clinical data, 
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including clinically isolated syndrome (CIS), conversion to clinically definite MS and 
occurrence of relapse, disability measured by EDSS and MSSS , Corpus callosum 
atrophy (CCA) need to be collected. Based on these data, the longitudinal cohort 
study can calculate a true odds ratio, hazard ratio, and confidence interval. However, 
each event (phenotype) for MS clinical takes many years to develop, this type of 
study design have a slow yield outcome and spend a lot of money.According to the 
small sample size of the most longitudinal study, P-value is hard to remain significant 
after multiple test. So several other epidemiological concepts should be done to 
suppo1t the results, including dose-dependency of allelic effect, internal consistency 
between related outcome measures (CDMS and relapse), and external consistency of 
directionality with associations found previously, as well as cumulative genetic risk 
scores. 
3. The role of genetic factors in MS onset and clinical course 
The role of HLA variants in MS onset 
Of the genetic loci implicated in MS onset, none has been as consistent in magnitude 
and significance as the HLA region. The HLA region of the genome encodes the 
major histocompatibility complex (MHC), a key element of adaptive immunity, and 
spans a region of about 4,000Kb located on the short arm of chromosome 6 at band 
position 6p2 l .3. It is the most complex genetic polymorphism system of the human 
genome. The MHC region is divided into three major regions: HLA class I, encoding 
the MHC I proteins; class II, encoding the MHC II proteins; and class III, which are 
partly of unknown function but appear to play some role in the general immune 
function and regulation(l8). The HLA class I and class II region are the most 
polymorphic region in human DNA sequences, leading to a great variety of 
genotypes, this a valuable component of adaptive immune recognition of the diverse 
number of epitopes to be recognised. The c lass I region contains HLA-A , HLA-8 and 
HLA-C genes, while the class II region contains HLA -DP, HLA -DQ and HLA-DR 
genes. Variants in this regions have been associated with most inflammatory and 
autoimmune disease such as multiple sclerosis. Bertrams and colleagues identified 
that HLA-A3 and HLA-87 were associated with MS onset(l9). Subsequent study has 
confirmed this finding(20). Altogether, HLA variants have explained 10.5% of the 
heritability of MS(21). Of the HLA loci, most studies have shown the HLA-
DRBJ *1501 locus to be the most strongly associated with MS risk (0R=3. l , 
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Pcombincd<I0.320)(22-24), connoting a three-fold greater risk of MS(25) . Several other 
HLA alleles and haplotypes have also been identified to be associated with MS onset, 
but these appear to vary in their assoc iation with risk by ancestry and ethnic ity. 
S tankovich and colleagues investigated HLA assoc iations in 1,230 MS cases in 
Austral ia, finding not only HLA -ORBI *1501 but also HLA-ORBI *03 to be associated 
with MS risk (26). In Turkey and the Canary Islands, HLA-ORB/ *04 was associated 
with the risk of MS(27), while in Sardinia, HLA-ORBI *0301 and HLA -ORBI *0401 
were identified as a genetic ri sk factor(27). MS patients in Canada and Sweden were 
assoc iated with HLA -ORBI */ 7(28). HLA-DRBI * /501 and HLA-OQB/ *0602 have an 
effect on in persons of African descent(23). Finally, even though Asian MS patients 
typically present as optico-spinal MS (OS-MS), in contrast to that seen in European-
descent populations, MS patients in Japan a lso were associated with HLA-
ORBI * 1501(29); and the incidence of MS patients with HLA-ORB/ *0405 was 
significantl y increased(30). Field and colleagues identified a relationship between MS 
and HLA ORB/ * 15:01, *0301 , *0401, *1303, HLA-A*0201 and HLA-OPB/ *0301 in 
1,6 18 MS case and 3,413 controls of European descent(3 1 ). A SNP in an intron of 
HLA-OPBI , rs3 135021, was al so assoc iated with MS in African Americans(24). In 
the same year, a Polish group that a polymorphism in the HLA-G gene was associated 
with MS susceptibility (32). In 20 12, Alcina and colleagues reported that the A allele 
of SNP rs3 135388 in ORB/ * /50/ was associated with DQB/, DRBI and ORB5 
genes' high expression in a Caucasian compared to G alle le (33). These data 
demonstrate a significant role fo r the ORB/ * /50/ locus in MS onset. Not only are 
these loc i associated with MS onset, but also there is some evidence showing that 
deleterious HLA genotypes like ORBJ *1501 were positively associated with a marker 
of disease, oligoclonal bands(OB), whi le protective variants like DRB/ *0405 were 
negatively associated with OB(34). These findings are usefu l in that they provide 
internal consistency validation to HLA being associated with MS. Another study 
reported that the late onset MS was significantly associated with HLA-DRBI *0801 
gene(35). 1.n 2009, Rama and other studies have found that HLA-DRJ 5* / 501 have a 
significant e ffect on the age of onset(AO) of MS among Caucasians and African-
Americans (36). 
As shown by Chao and colleagues, women catTy more MS risk allele H LA-ORB I * 15 
than men. The prevalence of MS among women is approximately twice as in 
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men(37). Even sharing of the same genes and environmental risks, the concordance 
rate for the development of MS between identical twins is only 6-30%(38-41 ). These 
suggest that there are other mechanisms behind the scenario. 
HLA & MS clinical course 
The polymorphisms of HLA (especially HLA-DRBl) were highly associated with MS 
onset. However, little evidence showed that HLA genes were associated MS clinical 
course. One Australia study with 1230 MS cases and 1210 controls find both the 
DRBJ *04 and DRBJ *01/DRBJ * 15 genotype protected against PPMS (26). In 2010, 
another Australian study identified that HLA-DRBJ * 1501 was correlated with MS 
severity as measured by MSSS; and HLA-DRBI *1201 allele was correlated with less 
severe disease (42). Silva A.Met al did a case and control study with 248 patients and 
282 healthy controls and reported that, in Portuguese, HLA-DRBJ * 15 allele was a risk 
factor for MS and HLA-DRBl * 15 patients cause a longer time to reach a high EDSS 
(EDSS=3 or EDSS=6).(43). This result was in line with Weatherby's study (44). 
However, another study has reported a contradictory result that the DRBl *01/04 and 
DRBJ *l 5115 cause a shorter time to reach a high EDSS (EDSS=6) (45). In 2003, 
Barcellos et al found that there is a worse MS disease course in individuals with HLA -
DR2(46). However, this result was not confirmed by subsequent study with a large 
sample size in the same group(47). In northeast Italy, HI.A-DR] 3 was associated with 
"benign" multiple sclerosis(48).But whether it can be taken as a prognostic factor 
need long time clinical follow up and large sample size. In west Australia, HLA-
DRBl *1501 was the strongest risk variants in RRMS and PPMS(49). The 
DRBl * 1501 also cause a worse disease course (50). Among African American MS 
patients, both DRBJ * 1501 and DRBJ * 1503 did not contribute to the disease severity, 
thus, MS severity was found to be associated with another gene or genes within HLA 
loci (51). 
In short, there were few results about the relationship between HLA variants and MS 
clinical course because the case control study was widely designed to identify the 
relationship between exposures and outcome. However, MS relapse and disability 
progression last a long time period which can be followed by longitudinal cohort 
study. Thus, based on above results, it is reasonable to assume that the HLA variants 
contribute to MS onset and initial triggering mechanisms rather than modulating MS 
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clinical course. The main contribution of HLA variants is the influences of MS onset. 
The role of non-HLA variants in MS onset & progression 
During the last few decades, utilising candidate-gene, linkage studies and genome-
wide association study (GW AS) approaches, at least 110 non-HLA genetic loci have 
been identified as associated with MS onset(25, 52-56). Most of these 110 variants' 
biological function still unclear, as yet, there are no benefits for MS treatment, based 
on GW AS result. Still, several are in regions of plausible relevance to MS, 
particularly those involved in immune function and those related to relevant 
environmental factors like vitamin D. Some of the most plausible will be summarised 
below. 
Interleukin 7 receptor (IL 7R) 
IL7R was the only non-HLA MS common risk variants identified by the candidate 
gene method(57), and was subsequently confirmed by the first GWAS in multiple 
sclerosis(58). IL7R plays an important role in Band T-cell differentiation. 
Functionally, IL7R also involved in the regulation of innate and adaptive immunity, 
and the absence of this regulation can yield an inflammatory immune response that 
can damage the myelin sheath(57). IL7 signalling is crucial for T-cell differentiation 
of CD4- CD8-thymocytes, CD4+ CDS+ cells survival, and immune homeostasis. The 
common variant, of the SNP rs6897932 in the IL7R gene, was allelic and functional 
associated with MS. This variant affects the brain and CNS, causing muscle 
weakness, poor coordination, numbness, and a variety of problems with the nervous 
system. The mode of effect for this SNP in neuropathology is potentially due to its 
role in differential transcription of the receptor protein. Beyond just impacting on 
disease risk, a recent study (270 cases, 303 controls) found that rs6897932 in IL7R 
was not only associated with MS susceptibility but also with disability progression in 
a Central European Slovak population: the allele C was a risk factor for MS, whereas 
the minor T allele was protective against both MS risk and against a more rapid 
disability progression (59). 
Interleukin 2 receptor alpha (IL2RA) 
There is a strong association between two variants of interleukin 2 receptor alpha 
(!L2RA) (OR: 1.19- 1.25) and MS risk (58). IL2RA involved in regulation ofT-cells 
and encoded the alpha chain of the interleukin-2 receptor. IL2RA chain also plays an 
Appendix 1A. Paper in Chapter 1 
 84 
important role in MS mechanism because the IL2RA pathway involved in patients' 
adaptive and innate immune response(60). One study finds the functional explain for 
IL2RA: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is strongly 
induced by interleukin 2 (!L-2). The polymorphisms in genes which in T helper (TH) 
cell differentiation pathway are associated with MS onset (61). Traboulsee and 
college found that IL2RA affected both MS onset and progression(62). 
TNFRSFlA 
TNFRSFJA encodes the p55 receptor for tumor necrosis factor alpha (TNFa). 
Previous studies show that dysregulation of the TNFa pathway may influence the risk 
of MS. The level of TNFa activity likely to be correlated with CNS inflammatory 
lesions. Studies also find that TNFRSFIA polymorphisms tended to have a second 
relapse within a year. TNFRSFJA not only associated with MS onset but also 
influenced the clinical course. One polymorphism (rs4149584) within 
TNFRSFJA cause an early MS onset and a slow MS progression(63). 
CXCRS 
Chemokine (C-X-C motif) receptor 5 also known as CDJ85. This gene encodes CXC 
chemokine receptor family proteins. CXCR5 is one kind of protein coding gene. One 
case control study found the polymorphisms (rs630923) of CXCR5 was associated 
with MS onset(64). In this study, rs630923 located into the transcription factor 
binding site of CXCR5(65). 
TNFSF14 
Tumor necrosis factor supe1family member 14 gene encodes the tumor necrosis 
factor(TNF) ligand family protein. This protein has been shown to stimulate the 
proliferation of T cells, which may influence the autoimmune response. One study 
with 477 MS cases and 481 control samples found the A allele of the polymorphism 
(rsl077667) in TNFSFJ4 gene have a protective effect on MS onset, whereas the G 
allele was a risk allele for MS onset. In addition, TNFSF14 was a microRNA target 
gene significantly decreased in MS. This result suggests that microRNA may 
influence the T-cell and molecules MS onset(66). 
In addition, few relationships between these associated variants and MS progression 
have been identified. In our own studies, a prospective longitudinal cohort study of 
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persons who had a first clinical episode of demyelination (FOE), followed for 5-years. 
We found that seven non-HLA SNPs of the 110 variants predicted re lapse and/or 
COMS, and seven other non-HLA SNPs predicted the annualised change in disability 
status (t.EOSS, as measured by Expanded Disability Status Scale). These results 
suggested that MS risk variants also influence MS clinical course (onset and 
progression). 
4. Gene-environment interactions 
Beyond genetic factors, many environmental factors have also been associated with 
MS onset and clinical course, such as vitamin O deficiency(67), smoking (68, 69) and 
EBY (Epstein-Barr virus) infection(70) . Importantly, there is emerging evidence 
suggesting that MS may be caused by an interplay of multiple variants and 
environmental factors. Studies have indicated that gene-environment interactions can 
explain a part of the MS missing heritability: some environmental situation with 
particular genetic variants brings a significantly greater effect on MS onset and 
c linical course(6, 71 , 72). 
Vitamin O response elements(YDRE) located in the promoter region of HLA-
DRBl */ 5:0 / , this locating suggests that different vitamin O situations might interact 
with HLA-ORB l to influence MS onset(73). The VORE modulates HLA-DRBI gene 
expression after stimulation with Vitamin D. In Austral ia, study with 466 MS cases 
and 498 controls showed that VORE interac t with different HLA-ORB I promoter 
region polymorphism causes an 11 fo ld range risk of MS onset. However, other 
studies showed that other environmental fac tors inte ract with HLA risk variants play 
more role in MS onset. Simila rly, the rate of progression of established MS is highly 
variable, e.g. monozygotic twins can have onsets of MS at significantly different ages, 
have complete ly diffe rent clinical presentations, and can progress at very different 
rates. This var iabil ity may be under genetic control or at least influenced by it. 
Currently, not many genes have been found that influence MS clinical course. The 
HLA-DRBI *1501 locus decreases the age of onset. Therefore, it is likely that genes 
that interact with environmental factors may significantly influence the rate o f MS 
clinical course and determine the different MS clinical course phenotype. It is thought 
that secondary progressive MS and PPMS represent the same pathological process 
and that MS relapses may represent a separate and additive inflammatory process 
more directl y infl uenced by environmental determinants. 
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Lin and colleagues using Cox proportional hazards regression models to estimate the 
relationship between known MS common risk variants and MS relapse; and whether 
these SNPs influence the 25-hydroxyvitamin D (25(0H)D) - relapse association 
among 141 RRMS patients in Southern Tasmanian Multiple Sclerosis Longitudinal 
Study (the MSL study)(6). They identified five variants associated with MS relapse 
with significant cumulative genotype risk effects. They also found three SNPs which 
modified the relationship between the hazard of relapse and serum 25(0H)D levels. 
Unfortunately, no risk variants were identified for MS disability progression. This 
study indicated that gene and environment interactions may play an important role in 
MS clinical course. It is a mechanism by which MS clinical is driven. It will provide 
suppo1t for the role of serum 25(0H)D in MS onset and progression. Similarly, 
another study using the same cohort showed protein kinase C (PKC) family genes-
25(0H)D interactions modulate MS clinical course(2). In this study, they identified 
two SNPs in PRKCZ and PRKCH interact with 25(0H)D levels to influence relapse. 
However, SNPs itself was not independently associated with hazard of relapse. They 
also found two SNPs within the CYP2Rl and PRKCB were associated with 25(0H)D 
levels in relapse. CYP2RJ has been previously identified to be associated with vitamin 
D levels in GW AS. The PRKCB gene has been previously associated with risk of 
rheumatoid arthritis and it is a member of the PKC gene family which is regulated 
by 1,25 dihydroxyvitamin D (l ,25(0H)D) in chondrocytes and mediated by VDR in 
downstream signalling pathways. These results suggest that gene-vitamin D 
interaction is associated with MS clinical course. 
CYP24Al and Vitamin D 
rs6013897 (p=6* 10-10) in CYP42Al has been previously identified to be associated 
with vitamin D levels in GW AS (74). Vitamin D gene influence MS onset and clinical 
course by modulating vitamin D levels. Vitamin D deficiency has been considered as 
a risk factor for many complex diseases such as MS. Recent study found that the low 
vitamin D level plays an important role in MS risk. A large number of 
epide miological data indicated that there is a high prevalence of MS in high-latitude 
and low ultraviolet radiation (UVR) cold area in contrast to the low prevalence of MS 
in low-latitude and high UVR warm area. This because Vitamin D3 is produced 
photochemically from 7-dehydrocholesterol in the skin by UVR(75). Then, vitamin 
D3 was absorbed by human body. Finally, vitamin D3 converted to 1,25-
dihydroxyvitamin D (l ,25(0H)2D3). Now, it was well established that Vitamin Din 
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humans mainly comes from sun exposure. Vitamin D play an essential role in the 
synthesis of myelin. Vitamin D as an environmental factor, not on ly influence 
whether a person will get MS but also impact the clinical course of MS. The 
invol vement of the vitamin D in the onset and progression of MS was related to the 
essential role that vitamin D pathway plays in the autoimmune system. The immune 
system is regulated by combining of the active form vitamin D (Hydroxylates 25-
hydroxyvitamin D) with the specific vitamin D receptor (VDR), and the function of 
VDR is regulated by its genetic structure. There are many restriction sites such as Bsm 
I and Apa I in VDR gene. One study suggests that the polymorphisms of the VDR 
gene may be associated with MS risk. Simpson and colleagues found that each 
I Onmol/1 increase in vitamin D resulted in a nearly 12% reduction of MS relapse risk 
by using survival analysis(67). This is the fi rst longitudinal cohort study to in vestigate 
the relationship between vitamin D and relapse of RRMS patients. The recent 
subsequent study shows evidence that Vitamin D plays an important role in myelin 
repair. This study finds vitamin D acti vated RXR gamma receptor protein and this 
protein was important in MS patients' myelin repairing (76). This finding functionally 
ex plained the relationship between the vitamin D level and progression of MS and 
indicated that vitamin D could be a targe t for the future myelin repair drug and a 
possible treatment for people with MS. In sho11, compared to other MS treatment, 
vitamin D based treatment are cheaper with fewer side effects. It is easier for people 
to inc rease vitamin D level by sun exposure and daily intake. 
Many research results bring the question tha t why a number of genetically susceptible 
indi viduals maintain healthy while others develop into the disease. One potential 
answer is genetic heterogeneity, and the other is gene-environmental interactions. 
Genetic epidemiology implies that genetic background has an important 
complementary role in MS onset. Lf genetic factors keep the same in individuals, the 
environment determines the threshold of MS onset(77). 
5. Epigenetic 
Recently, major progress has suggested that epigenetic mechanism contributes to the 
pathophysiology of MS. These partly mediate the response to environmental 
influences and changes in gene expression. Epigenetics is known as heritable changes 
in gene expression yet not modifying underlying DNA sequence(78).ln multiple 
Appendix 1A. Paper in Chapter 1 
 88 
sclerosis, epigenetic changes mediate the response to environmental factors (5, 79) 
and then change gene's expression. The epigenetic mechanisms consist ofhistone 
modification, DNA methylation and nuRNA-associated post-transcriptional gene 
silencing(80). The import finding of epigenetic processes in cells are DNA 
methylation and histone deacetylation. MS usually transmitted to children more by 
female than male implies an epigenetic contribution(8 I ). The potential reason for this 
parent effect might be the Hl.A-DRBI * /5:01 a llele, which is the major genetic risk 
factor for MS and regulated by epigenetic such as DNA methylation, histone 
deacetylation, and mi RNA-associated silencing. 
Epigenetic changes can explain much of heterogeneity in MS clinical course. For 
example, gene methylation of MS patient's blood study found DNA methylation may 
be used as markers of MS disease activity (82). Study on methylation changes in 
cancer patients 56 genes show that 15 genes in the cell -free plasma DNA occur 
methylation in MS patients and healthy controls group, further, that 5 in 15 genes 
promote methylation of genes may a lso disti nguishing patients with remission and 
exacerbation. Another study showed thatmiRNA-572 was significantly upregulated 
and downregulated during MS cli nical course such as disease relapse and remission 
phases. This result indicated that miRNA-572 can be a biomarker for 
remyelination(83). These results suggest that all these microRNAs might be potential 
targets for the treatment of MS. 
The epigenetics contribution to MS is just beginning to come to light, several 
mechani sms of epigenetic change in patients with MS were identi fied. Believing that 
there will be more findings in the near future. l t has opened a new era to us in MS 
research. DNA demethylation of epigenetic, histone deacetylation and regulation 
mechanism of miRNA opened up enticing prospect of new therapies for MS. There is 
a vast potentia l to use epigenetics for both MS preventive treatments and personalised 
therapies. It also brings a great hope to develop complex diseases' molecular targeted 
genome research(84, 85). Epigenetics became the newest MS genetic research method 
in fu ture. 
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6. Challenges for future research in MS genetic epidemiology 
Cl inical application: Translational medic ine- translating predicti ve factors (GWAS 
results, epigenetic results) to clinical application. Let doctor and patient to know 
genetic informat ion easily. 
Bio logical implications: To test whether GW AS results indicated new mechanisms of 
MS. Ide nti fy potential polymorphism targets, gene coding functi ons, and e pigenetic 
regulation. 
Large magnitude: The effect of one non-HLA common variant were small. (OR 
ranging from 1. 1-1.5). There has been a cumulati ve e ffect of many variants into a 
c umulative genetic risk score for greater clinical utility. 
7. Conclusions and future directions 
During last decades, major progress has bee n made in identi fying MS susceptibil ity 
genes. ln partic ular, the role of HLA loci has been fairly well substantiated, but 
rece ntly othe r non-HLA genes, including those involved in immune function and 
vitamin D metabolism, among others, have been indicated. However. while the role of 
these loci in MS onset has made great strides, there has been comparative ly less 
success in examining these factors' role in MS c linical course. While there are 
methodological hindrances to success in this area, it may also be due to the 
complexity and inte r-patient heterogeneity in d isease progression, to say nothing of 
the potential confounding impacts of post-onset behavioural changes and disease-
modifying therapies. All that said, there is hope for the future. The new discovery will 
depend on large biological samples, compre hensive databases of 
e nvironmenta l/be havioural, genetic and c li nical factors, new genetic technologies and 
statistical models. Further research of MS s usceptibility genes may lead to a better 
understanding of MS susceptibility & pathogenesis, and potentially to a more 
persona lised medical treatment approach. 
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